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Abstract 
 
This retrospective study presents the Swiss Canine Cancer Registry, containing pathology 
diagnostic records compiled between 1955 and 2008 by three veterinary diagnostic laboratories in 
Switzerland. The data set was investigated systematically covering various points of interest. The 
results were published in two articles in the Journal of Comparative Pathology. The first article (The 
Swiss Canine Cancer Registry: a retrospective study on the occurrence of tumours in dogs in 
Switzerland from 1955 – 2008) presents a broad overview on the whole data set. In the second 
article (Swiss Canine Cancer Registry 1955 – 2008: Occurrence of the most common tumour 
diagnoses and influence of age, breed, body size, sex and castration status on tumour development) 
tumours were investigated in small groups for a better comparison with other canine cancer 
registries and clinical relevance. Analyses of the influence of age, breed, body size, sex and 
castration status on dogs’ tumour development were carried out using multiple logistic regression. 
The sample size allows detailed insight into the influences of age, breed, body size, sex and 
castration status on canine tumour development. It is hoped that this study marks the beginning of 
continuous registration of dog tumours in Switzerland, which will serve as a reference for research 
in the fields of animal and human oncology. 
Keywords: tumour, dog, cancer registry, statistical risk analyses 
 
Zusammenfassung 
 
In dieser retrospektiven Studie wurde das Schweizer Hundekrebsregister erstellt und ausgewertet, 
dessen zu Grunde liegenden Diagnoseberichte aus drei Veterinärpathologischen Instituten in der 
Schweiz und dem Zeitraum von 1955 bis 2008 stammen. Die Ergebnisse der Auswertungen wurden 
in zwei Artikeln im Journal of Comparative Pathology veröffentlicht. Der erste Artikel (The Swiss 
Canine Cancer Registry: a retrospective study on the occurrence of tumours in dogs in Switzerland 
from 1955 – 2008) gewährt einen breiten Überblick über das Tumorvorkommen bei den Schweizer 
Hunden. Im zweiten Artikel (Swiss Canine Cancer Registry 1955 – 2008: Occurrence of the most 
common tumour diagnoses and influence of age, breed, body size, sex and castration status on 
tumour development) wurden die Tumoren zu Gunsten besserer Vergleichbarkeit und klinischer 
Relevanz in differenzierten Untergruppen untersucht. Mittels multipler logistischer 
Regressionsanalysen wurde der Einfluss von Alter, Rasse, Körpergrösse, Geschlecht und 
Kastrationsstatus auf die Entwicklung der Tumoren untersucht. Die grosse Datenmenge erlaubte 
detaillierte Einsichten über die Einflüsse dieser Variablen auf die Tumorentwicklung.  
 
Es ist wünschenswert, dass diese Dissertation das Fundament für ein fortlaufendes Schweizer 
Hundekrebsregister bildet und weiteren Forschungsarbeiten im Gebiet der Onkologie für Mensch 
und Tier als Grundlage dient. 
 
Stichworte: Tumor, Hund, Krebsregister, statistische Risikoanalysen  
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The Swiss Canine Cancer Registry: A Retrospective
Study on the Occurrence of Tumours in Dogs in
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Summary
Diagnostic records are a key feature of any cancer epidemiology, prevention or control strategy for man and
animals. Therefore, the information stored in human and animal cancer registries is essential for undertaking
comparative epidemiological, pathogenic and therapeutic research. This study presents the Swiss Canine Can-
cer Registry, containing case data compiled between 1955 and 2008. The data consist of pathology diagnostic
records issued by three veterinary diagnostic laboratories in Switzerland. The tumours were classified accord-
ing to the guidelines of the International Classification of Oncology for Humans on the basis of tumour type,
malignancy and body location. The dogs were classified according to breed, age, sex, neuter status and place of
residence. The diagnostic datawere correlatedwith data on the Swiss general dog population and the incidence
of cancer in dogs was thus investigated. A total of 67,943 tumours were diagnosed in 121,963 dogs and 47.07%
of these were malignant. The most common tumour location was the skin (37.05%), followed by mammary
glands (23.55%) and soft tissue (13.66%). The most common tumour diagnoses were epithelial (38.45%),
mesenchymal (35.10%) and lymphoid tumours (13.23%). The results are compared with data in other canine
registries and similarities in tumour distribution and incidence are noted. It is hoped that this study will mark
the beginning of continuous registration of dog tumours in Switzerland, which, in turn, will serve as a reference
for research in the fields of animal and human oncology.
! 2015 Elsevier Ltd. All rights reserved.
Keywords: cancer registry; dog; epidemiology
Introduction
Cancer is a leading cause of death in man and dogs
(Pinho et al., 2012); however, current medical
research is hampered by the complex biology of the
disease. Murine cancer models are highly standard-
ized and have contributed tremendously to knowl-
edge of cancer mechanisms and treatment regimes,
but such models are often limited in representing spe-
cific aspects of spontaneously arising human cancer
such as long time latency, recurrence and metastasis
(Porello et al., 2006; Thamm and Dow, 2009;
Marti"c-Kehl et al., 2012; Ranieri et al., 2013). Such
information is best derived from cancer registries,
which provide data on the epidemiology of cancer
over space and time. In many countries, human
cancer registration has been practiced since the
1940s (Brønden et al., 2007).
Companion animal cancer registries were intro-
duced in the 1960s, following increasing mortality
J. Comp. Path. 2015, Vol. 152, 161e171 Available online at www.sciencedirect.com
ScienceDirect
www.elsevier.com/locate/jcpa
Correspondence to: A. Pospischil (e-mail: apos@vetpath.uzh.ch).
0021-9975/$ - see front matter ! 2015 Elsevier Ltd. All rights reserved.
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due to spontaneously arising tumours. The study of
companion animal tumours offers benefits not only
for animal epidemiology, but also for comparative
epidemiological, pathogenic and therapeutic
research. Companion animals have a life span that al-
lows them to develop tumours resembling equivalent
human cancers in their morphology and biological
behaviour. Companion animals also benefit from
oncological therapies that are used in human medi-
cine. Companion animals share the same environ-
ment as their owners and can therefore act as
sentinels for recognition of environmental factors
implicated in oncogenesis (Bukowski and
Wartenberg, 1997; Backer et al., 2001; Gamlem
et al., 2008; Marconato et al., 2009; Bettini et al.,
2010). Companion animals, and dogs in particular,
share significantly more of their genome with man
than do rodents (Pinho et al., 2012). Therefore, inves-
tigations of spontaneously arising cancer in dogs can
provide a partial alternative to animal testing
(Bukowski and Wartenberg, 1997; Thamm and
Dow, 2009).
In the 1960s and 1970s three population-based an-
imal registries were reported in the USA: the Califor-
nia Animal Neoplasm Registry (1963e1966; Dorn,
1967), the Kansas University Neoplasm Registry
(1961e1971; Strafuss, 1976) and the Tulsa Registry
of Canine and Feline Neoplasms (1972e1977;
MacVean et al., 1978). Since the late 1980s several an-
imal cancer registries have been established and are
still being updated: the Purdue Comparative
Oncology Program (since 1979; Purdue
Comparative Oncology Program, 2006), the Cancer
Registry and Surveillance System for CompanionAn-
imals, Cornell (since 1980; Page, 2004), the Animal
Tumour Registry of Genoa (since 1985; Merlo et al.,
2008), the Norwegian Cancer Project (since 1990;
Gamlem et al., 2008), the VetCancer Registry (since
1994; Brønden et al., 2007), the Registry on Canine
Tumours in Sweden/Agria (since 1995; Egenvall
et al., 2011), the Danish Veterinary Cancer Registry
(since 2005; Brønden et al., 2010), the Animal
Tumour Registry of the Vicenza and Venice prov-
inces (since 2009; Vascellari et al., 2009) and the
Guelph Companion Animal Cancer Epidemiologic
Registry (since 2010; Nødtvedt et al., 2011).
The Swiss Canine Cancer Registry (1955e2008)
was assembled as part of the project ‘One Medicine
e One Oncology: Incidence and Geographic Distri-
bution of Companion Animal Cancer in Switzerland,
1955e2008’. Additionally, the project benefits from
information about the general canine population at
risk, since microchipping and registration of dogs in
Switzerland has been compulsory since 2006. The
general dog population was surveyed with an accu-
racy reaching 95% in 2008 (personal information,
Gesellschaft Schweizer Tier€arztinnen und Tier€arzte,
the Swiss Society of Veterinarians). These latest
data, together with data originating from previous
research on the Swiss general dog population, allows
data in the registry to be analysed against the back-
ground of the total population of dogs in Switzerland
(Pospischil et al., 2013).
The aim of this paper is to present the Swiss Canine
Cancer Registry, which was compiled between 1955
and 2008. Data consists of pathology diagnostic re-
cords issued by three veterinary diagnostic labora-
tories in Switzerland. The tumours were classified
according to the guidelines of the International Clas-
sification of Oncology for Humans (ICD-O-3) on the
basis of tumour type, malignancy and body location
(WHO, 2013). The dogs were classified according
to breed, age, sex, neuter status and place of residence.
The analysis provides a retrospective overview of the
incidence of malignant and benign neoplasms in the
Swiss canine population. The findings are related to
the general dog population and the tumours are char-
acterized by type, biological behaviour, body loca-
tion, age of animal and diagnostic method.
Materials and Methods
Data Source
The dog tumour registry comprises 121,963 diag-
nostic records provided by three veterinary diagnostic
laboratories in Switzerland: the Vetsuisse Faculty, In-
stitut f€ur Veterin€arpathologie, Z€urich (IVPZ), the
Institut f€ur Tierpathologie, Bern (ITP) and the
Zyto-Histo Diagnostics private veterinary diagnostic
laboratory (based in Rorbas Freienstein).
The IVPZ provided three sets of diagnostic records
(n ¼ 97,759; 1955e2008) from canine post-mortem,
biopsy and cytology samples. The datasets originated
from three time periods during the history of this insti-
tution. The IVPZ-GL (1955e1964) provided 3,797
records from canine post-mortem samples. These re-
cords were originally handwritten documents that
were later digitized in an Excel file. The IVPZ-SLK
(1964e1988) provided 33,100 records from canine
post-mortem and biopsy samples. These records
were originally transcribed onto punch cards using
diagnostic key words (Keydex, Fa. Royal McBee;
St€unzi and Lott-Stolz, 1967) and were digitized by
Scydoc, an external company based in Zug,
Switzerland. The results were crosschecked using
the original typed reports. The IVPZ-APPX
(1987e2008) provided 60,862 records from canine
post-mortem, biopsy and cytology samples. The re-
cords were stored in the electronic patient record
162 K. Gr€untzig et al.
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system of the IVPZ. In 1987, when the digitized
collection of data started, a punch card system was
still used. There was no overlapping of data since
dogs were only recorded in one system.
The ITP provided a set of diagnostic records
(n ¼ 20,674; 1983e2008) from canine post-mortem
and biopsy samples and Zyto-Histo Diagnostics pro-
vided a set of diagnostic records (n ¼ 3,530;
2007e2008) from canine biopsy samples. All samples
from the IVPZ, ITP and Zyto-Histo Diagnostics were
examined by histopathology.
Data Preparation
The datasets were compiled in a FileMaker database,
which was exported into a Stata database (StataCorp
LP, College Station, Texas, USA). Individual diag-
nostic records were standardized according to age,
sex, neuter status and breed. The diagnoses were
then coded according to the tumour topographical
and morphological keys of the ICD-O-3 (Tables 1
and 2) and checked for plausibility using the
original patient records. All tumour diagnoses were
confirmed by histopathology. Epidermal cysts were
excluded. Diagnoses were grouped for future
comparison with human cancer and for this reason
some of the groups may be unusual for veterinary
pathologists. The groups are described in Table 3.
The term ‘epithelial tumour’ is used in two different
ways: firstly as an overall group including all types
of epithelial tumours and secondly as a narrow group:
‘epithelial* tumour’ (Table 3).
Tumour groups included both malignant and
benign tumours (i.e. adenoma and adenocarcinoma
were categorized as one group ‘adenoma, adenocarci-
noma’). Each diagnostic record gave information
about the tumour malignancy grade in an additional
field. To investigate malignancy, each tumour group
was divided into ‘benign’ (malignancy grade 0e2)
and ‘malignant’ (malignancy grade 3e6) according
to the ICD-O-3 classification. Because benign tu-
mours can develop into malignant tumours of the
same type, tumours such as adenoma and adenocarci-
noma were not treated as separate groups. The same
procedure was applied to related tumour groups; for
example, lymphangioma and lymphangiosarcoma,
osteoma and osteosarcoma, naevi and melanoma,
myxoma and myxosarcoma. As different pathologists
had worked on the samples, there were two different
approaches to specifying the location of fibrosarcomas
in subcutaneous tissue. Some pathologists used ‘skin’
as the location because skin biopsy was used to collect
the sample, while others used ‘soft tissue’ to describe
the origin of the tumours. We combined these two lo-
cations and recoded ‘skin’ as ‘soft tissue’ for fibrosar-
comas.
Breed allocation was based on information in the
diagnostic records. Mixed breed dogs were assigned
according to the first-named breed or were classed
non-specifically as crossbreed dogs. The 17 most com-
mon breeds, each comprising >900 individuals, were
investigated further. The remaining breeds and re-
cords in which breed was recorded as ‘unknown’
were listed as ‘other breeds’. The breed category
‘shepherd’ included German shepherd dogs, Beau-
ceron Berger de Beauce, white shepherd dogs, Berger
de Picardie, Berger de Savoie, Berger des Pyr!en!ees,
Groenendael, Laekenois, Malinois and Tervueren.
Diagnostic records for dogs residing outside
Switzerland were excluded from the analysis.
Table 1
Coding and grading of tumour diagnoses according to
ICD-O-3
Diagnosis ICD-O code
Odontogenic neoplasia ICD-O 9270e9330
Trophoblastic tumours ICD-O 9104
Epithelial tumour ICD-O 8010e8587,
ICD-O 9050e9058
Germ cell tumour ICD-O 9060e9085
Lymphangioma,
lymphangiosarcoma
ICD-O 9590e9960
Lymphoid tumour ICD-O 9590e9960
Melanoma ICD-O 8720e8730
Mesenchymal tumour ICD-O 8680e8711,
ICD-O 8800e9040,
ICD-O 9120e9150,
ICD-O 9580
Skeletal tumour ICD-O 9180e9262
Neural tumour ICD-O 9380e9570
Gonadal tumours ICD-O 8610e8670
Unspecified tumours ICD-O 8000
Table 2
Coding of tumour locations according to ICD-O-3
Location ICD-O C code
Blood, haemopoietic system ICD-O C 42
Neoplasia of bones, joints, cartilage ICD-O C 40e41
Brain, meninges, other parts of CNS ICD-O C 70e72
Mammary gland ICD-O C 50
Endocrine gland ICD-O C 73e75
Gastrointestinal tract ICD-O C 16e26.8
Lymph nodes ICD-O C 77
Male sexual organs ICD-O C 60e63.2
Oral cavity, pharynx ICD-O C 2.9e11
Other female sex organs ICD-O C 51e58
Peripheral nerves, autonomic nervous system ICD-O C 47
Respiratory system, intrathoracic organs ICD-O C 30e39
Retroperitoneum, peritoneum ICD-O C 48
Skin ICD-O C 44
Soft tissues ICD-O C 49
Urinary organs ICD-O C 67e68
The Swiss Canine Cancer Registry 163
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1 Table 3 was corrected. See corrigendum page 15. 
Results
Dataset
Atotal of 121,963dogswere examined throughhistopa-
thology, ofwhich63,214 (51.83%)werediagnosedwith
tumours. Of those, 59,124 (93.53%) had a single
tumour and4,090 (6.47%)hadmultiple tumours.A to-
tal of 35,232 (52.93%) of the tumours were benign and
31,336 (47.07%) were malignant. The proportion of
tumour bearing patients versus patients without a
tumour differed according to the method of examina-
tion: by biopsy histopathology 64.81% of the patients
were diagnosedwith a tumour, by cytological examina-
tion41.96%andbypost-mortemexamination31.04%.
Table 3
Example of tumour grouping for four selected groups
Diagnosis group Single diagnosis Number Percentage [%]
Skeletal tumour ICD-O 9180e9262 Adamantinoma of long bones 103 8.7
Chondroblastoma 22 1.86
Chondroma, fibrochondrosarcoma 168 14.19
Osteochondroma 11 0.93
Osteofibroma 38 3.21
Osteoma, osteosarcoma 842 71.11
Total of skeletal tumours 1,184 100
Gonadal tumours ICD-O
8610e8670
Granulosa cell tumour, granulosa cell carcinoma 93 8.72
Leydig cell tumour 450 42.17
Luteoma 9 0.84
Sertoli cell adenoma, Sertoli cell carcinoma 423 39.64
Sertoli-Leydig cell tumour 92 8.62
Total of gonadal tumours 1,067 100
Gonadal germ cell tumour ICD-O
9060e9085
Embryonal carcinoma 3 0.45
Seminoma 632 95.47
Teratoma 8 1.21
Germ cell tumours 19 2.87
Total of germ cell tumours 662 100
Epithelial tumour ICD-O
8010e8587, ICD-O 9050e9058
Adenocarcinoma of anal glands 2,421 9.27
Adenocarcinoma with squamous metaplasia 190 0.73
Adenoma, adenocarcinoma 12,348 47.27
Adenomatous polyp, adenocarcinoma in adenomatous polyp 321 1.23
Adrenal cortical adenoma, adrenal cortical adenocarinoma 168 0.64
Basal cell carcinoma, adenoma 499 1.91
Carcinoma, anaplastic type 296 1.13
Cholangioma, cholangiocarcinoma 48 0.18
Composite carcinoid 43 0.16
Epithelial* tumour ICD-O 8010e9053 1,677 6.42
Epithelioid mesothelioma 37 0.14
Epithelioma 958 3.67
Hepatoma, hepatocarcinoma 155 0.59
Insulinoma 52 0.2
Intracystic papillary adenoma, intracystic papillary adenocarcinoma 79 0.3
Intraductal papilloma, intraductal papi 12 0.05
Mesothelioma, biphasic, malignant 42 0.16
Multifocal superficial basal cell carcinoma 231 0.88
Papillary adenoma, adenocarcinoma 112 0.43
Papillary carcinoma 871 3.33
Pilomatrixoma 503 1.93
Pulmonary adenomatosis, bronchiolo-alveolar adenocarcinoma 45 0.17
Sebaceous adenoma, sebaceous adenocarcinoma 1,456 5.57
Secretory carcinoma of the mammary gland 329 1.26
Spindle cell carcinoma 72 0.28
Squamous cell carcinoma 1,324 5.07
Squamous papillomatosis 10 0.04
Sweat gland adenoma, sweat gland adenocarcinoma 427 1.63
Thymoma 96 0.37
Transitional cell papilloma, transitional cell carcinoma 168 0.64
Trichoepithelioma 1,132 4.33
Total of epithelial tumours 26,122 100
164 K. Gr€untzig et al.
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Breed Distribution
The dataset included 182 different dog breeds
(n ¼ 101,281). A large number of these were cross-
breeds (n ¼ 12,193) and some were of unclassified
breed (n ¼ 8,489). The most frequent breed was the
Shepherd dog (10.13%), closely followed by cross-
breeds (10.00%) and retrievers (9.37%) (Table 4).
Incidence Rates
Fig. 1 shows the influence of the examinationmethods
on the annual tumour incidence rate. Post-mortem
examination had a relatively stable annual incidence
rate: 13 cases of neoplasia per 100,000 dogs in 1955
and 20 cases in 2008. A peak of 65 cases per 100,000
dogs was observed in the 1980s. Conversely, the over-
all annual tumour incidence rate rose from 13 cases of
neoplasia per 100,000 dogs in 1955 to 695 cases in
2008. This trend is comparable with the rise in the
incidence rate of biopsy and cytology cases, which
increased from 141 cases of neoplasia per 100,000
dogs in 1968 to 675 cases in 2008.
Distribution of the Most Common Diagnoses
Themost common tumours were epithelial (38.45%),
mesenchymal (35.1%), lymphoid (13.23%), mela-
noma (3.90%), skeletal (1.74%) and gonadal tu-
mours (1.57%). Fig. 2 presents a more detailed
distribution of the diagnoses, with adenoma and
adenocarcinoma (32.62%) at the top (see Fig. 3).
The Most Prevalent Diagnoses over Time
(1955e2008). The proportion of epithelial tumours
declined from 45.65% in 1955 to 34.46% in 2008,
while the proportions of mesenchymal and lymphoid
tumours, melanoma and gonadal tumours rose.
Mesenchymal tumours rose from 28.26% in 1955 to
34.36% in 2008, lymphoid tumours from 8.70% to
14.69%, melanoma from 0.00% to 5.18% and
gonadal tumours from 0.00% to 2.47% (Fig. 2).
Malignancy of the Most Common Tumour Diagnoses. Of
the total tumours, 47.07% were malignant. The
following tumour groups hadmalignancy rates higher
than the overall rate: skeletal tumours (96.61%), mel-
anoma (87.21%), gonadal germ cell tumours
(86.38%), epithelial tumours (56.52%) and
lymphoid tumours (52.79%). The following tumour
groups had malignancy rates lower than the overall
Table 4
The 17 most common breeds out of a total of 183 breeds
among 121,963 dogs
Breed Number Percentage [%]
Shepherd 12,354 10.13%
Crossbreed 12,193 10.00%
Retriever 11,429 9.37%
Swiss Mountain dog 7,774 6.37%
Poodle 7,214 5.91%
Dachshund 6,499 5.33%
Boxer 6,368 5.22%
Schnauzer 2,796 2.29%
Collie 2,206 1.81%
Yorkshire terrier 2,157 1.77%
Cocker spaniel 2,127 1.74%
Setter 2,105 1.73%
Great Dane 1,598 1.31%
Doberman pinscher 1,596 1.31%
Rottweiler 1,470 1.21%
West Highland white terrier 1,316 1.08%
Bulldog 1,016 0.83%
Parson Jack Russell terrier 981 0.80%
Other breeds (including dogs
of unknown breed)
38,764 31.78%
Total of all breeds 121,963 100%
700
600
500
400
IR
300
200
100
0
1955 1960 1965 1970 1975 1980
Year
All examination methods
Histology and cytology
Post-mortem examination
1985 1990 1995 2000 2005
Fig. 1. The influence of examination methods on the annual
tumour incidence rate (IR; i.e. number of tumours diag-
nosed per 100,000 dogs in the Swiss dog population).
Adenoma, adenocarcinoma
N.O.S. stands for "not otherwise specified".
Complex mixed tumour, neoplasia of stroma
Fibroma, fibrosarcoma
Mastocytoma, mast cell sarcoma
Neoplasia of blood vessels
Lipoma, liposarcoma
Soft tissue sarcoma, Sarcoma N.O.S.
Epithelial* tumour
Lymphoma
Unclassified neoplasm
Naevi and melanoma
Gonadal tumour
Skeletal tumour
Histiocytic neoplasam
32.62
8.49
6.5
5.66
5.47
4.42
4.42
4.35
4.08
3.9
1.57
1.54
1.11
0 10 20 30 40
%
9.59
Fig. 2. Detailed most common tumour diagnoses (>1% of
n ¼ 67,943).
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rate: neural tumours (43.38%), unclassified neo-
plasms (32.6%), mesenchymal tumours (29.65%),
lymphangioma and lymphangiosarcoma (16.09%),
gonadal tumours (8.15%) and odontogenic tumours
(2.67%). Fig. 4 presents the malignancy rate of the
most frequently occurring tumour groups.
A more accurate grouping shows that the following
tumour groups had malignancy rates higher than the
overall rate: mesothelial neoplasia (100%), complex
epithelial neoplasia (99.47%), leukaemia (99.39%),
transitional cell papilloma, transitional cell carci-
noma (98.21%), other neoplasia of bones (96.45%),
osteoma and osteosarcoma (95.49%), glial neoplasia
(94.26%), epithelial* tumour (89.97%), soft tissue
sarcoma (88.24%), naevi and melanoma (87.21%),
gonadal germ cell tumour (86.38%), myxoma and
myxosarcoma (83.24%), plasma cell neoplasia
(82.44%), synovia-like neoplasia (53.49%), histiocyt-
ic neoplasia (52.13%), adenoma and adenocarci-
noma (50.79%) and paraganglioma (48.5%).
Location of Tumours
Most of the tumours were located in the skin
(32.29%), the mammary gland (20.53%) and the
soft tissue (11.90%). Fig. 5 shows that the frequency
of tumours in all other locations was below 10%.
Due to the evaluation of all organs in post-mortem in-
vestigations, the distribution of locations of tumours is
unbiased, as compared with biopsy and cytology sam-
ples (Fig. 6). The gastrointestinal tract (11.40%) and
the respiratory system (10.63%) were the leading
tumour locations. The largest variety of tumour types
was found in themouth and the pharynx, where seven
different tumour types were identified (Fig. 7).
Age Distribution
The age distribution of the cases (Fig. 8) shows that
most dogs, irrespective of tumour presence, were be-
tween 5 and 10 years of age (48.79%). Another large
group consisted of dogs >10 years of age (21.42%).
Only 16.80% of the dogs were between 1 and 5 years
of age, and the group of dogs <1 year of age (6.84%)
mainly consisted of animals without tumours (see
Figs. 9 and 10).
Discussion
To our knowledge, the figures of 121,963 dogs and
67,943 tumour diagnoses collected over 53 years ren-
ders the Swiss Canine Cancer Registry the most
comprehensive animal cancer registry at a national
1955 1960 1965 1970 1975 1980
Year
Epithelial tumour Lymphoid tumour
Mesenchymal tumour
Gonadal tumour
Melanoma
1985 1990 1995 2000 2005
60
50
40
30%
20
10
0
Fig. 3. The yearly most prevalent tumour diagnoses. The percent-
age of a tumour type among all tumour types diagnosed per
year.
Epithelial tumour
Lymphoid tumour
Mesenchymal tumour
Gonadal tumour
Skeletal tumour
Melanoma
56%
30%
53%
87%
96%
8%
0 25,0005,000 10,000 15,000
n
Malignant Benign
20,000
Fig. 4. Absolute (n) and relative (%) distribution of the malig-
nancy in tumour diagnoses. In this figure, epithelial
tumour includes ICD-O 8010e8587 and ICD-O
9050e9058.
n = 67,943
32.29
20.53
12.84
11.9
7.49
3.86
2.09
2.09
1.59
1.26
1.24
.89
.55
.43
.42
.24
.23
.05
0 10
Skin
Mammary gland
Unclassified
Soft tissues
Gastrointestinal tract
Male sexual organs
Respiratory system, intrathoracic organs
Blood, haematopoietic system
Bones, joints, articular cartilage
Endocrine glands
Oral cavity, pharynx
Other female sexual organs
Urinary organs
Brain, meninges, other parts of CNS
Lymph nodes
Retroperitoneum, peritoneum
Peripheral nerves, autonomic nervous system
Eyes, organs of perception
20
%
30
Fig. 5. Distribution of tumour locations diagnosed by all examina-
tion methods. n, number of all samples; %, proportion of
tumour location.
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level. However, there are some shortcomings, which
are typical of long-term retrospective studies. One
such issue is that diagnoses were made by different pa-
thologists at different time periods. The criteria for
certain diagnoses may have changed over time and
in some cases there may be a subjective factor in his-
topathological diagnostics. This problem was over-
come by restricting data evaluation to those tumour
entities that could be clearly identified and that
have been known for a long time.
The yearly distribution of breeds in the Swiss
Canine Cancer Registry reflects the change in breed
fashion in the Swiss dog population (Pospischil et al.,
2013). In the 1950s and 1960s, poodles (13.80%),
shepherds (12.66%), crossbreeds (10.61%), boxers
(9.75%) and dachshunds (9.69%) were the most
common breeds. From 1970 to 2008 the most com-
mon breeds were crossbreeds (10%), retrievers
(9.97%), shepherds (9.87%) and Swiss Mountain
dogs (6.53%).
During the study period, the Swiss dog population
increased constantly and the relative tumour inci-
dence rose dramatically, from 13 cases per 100,000
dogs at risk in 1955 to 695 in 2008. This trend could
be explained by selection bias, due to the availability
of new diagnostic methods, namely biopsy sampling
(since 1968) and fine needle aspiration (since 1991).
This trend may also have been influenced by a rising
prevalence of tumours in dogs. In fact, similar to man,
the life expectancy of dogs has risen continuously since
1955, due to advancements in veterinary medicine.
An increased life expectancy, however, makes dogs
more susceptible to tumours, since tumours tend to
develop at an older age (Bonnett and Egenvall, 2010).
On the other hand, the tumour incidence rate in
post-mortem samples did not increase over time.
This might be explained partly by the decreasing rela-
tive number of post-mortem investigations, as dog
owners increasingly tend to refuse a post-mortem ex-
amination. Moreover, since the introduction of bi-
opsy sampling, tumours may have been diagnosed
before death, so that a post-mortem investigation
was no longer necessary.
Several additional factors may have contributed to
the increasing canine tumour incidence rate in
Switzerland. Firstly, the change in the role of dogs
in society, fromworking dogs to familymembers, fully
entitled to veterinary care, diagnostic examinations
and therapeutic interventions. Secondly, the stan-
dard of living has generally risen over the years and
dog owners can afford systematic diagnostic examina-
tions. Thirdly, the density of licensed veterinary prac-
tices increased from two practices per 100,000 dogs to
346 practices per 100,000 dogs in Switzerland be-
tween 1955 and 2008 (personal information,
Gesellschaft Schweizer Tier€arztinnen und Tier€arzte,
the Swiss Society of Veterinarians). Fourthly, the evo-
lution of environmental risk factors (e.g. UV radia-
tion or air pollution) may have encouraged tumour
development (Reif and Cohen, 1979; Porello et al.,
2006). Environmental factors responsible for dog
tumours should be investigated in future research.
It is generally difficult to compare tumour inci-
dences between animal cancer registries because of
differences in the sampling methods (MacVean
et al., 1978; Brønden et al., 2007, 2010; Vascellari
et al., 2009; Egenvall et al., 2011). In order to
estimate the population at risk, a telephone survey
was undertaken in Northern Italy (Vascellari et al.,
2009). Data were collected from an animal health in-
surance company (Agria Ltd.) in Sweden (Egenvall
et al., 2011) or by counting the ‘veterinarian-using’
dogs in Tulsa, USA (MacVean et al., 1978) and by le-
gally regulated dog registration in Denmark in the
Danish Dog Registry (Brønden et al., 2010) and, since
2006, in Switzerland.
However, in Switzerland, the tumour incidence
rate for 2008, which reached a value of 695 cases
per 100,000 dogs, lies midway between the rates of
other countries. For example, 282 cases per 100,000
dogs were observed in Northern Italy (Vascellari
et al., 2009), 500 cases per 100,000 dogs in Sweden
(Egenvall et al., 2005), 748 cases per 100,000 dogs in
the UK (Dobson et al., 2002) and 1,416 tumours per
100,000 dogs in Tulsa, USA (MacVean et al., 1978).
The observed malignancy distribution (47.07%) is
similar to that of other cancer registries. It was re-
ported as 38% by Brønden et al. (2010), 50% by
n = 8,614
19.9
11.4
10.63
9.62
8.59
7.34
7.2
6.77
4.97
3.88
2.79
1.53
1.81
1.25
1.14
.91
.17
.1
0 10
Skin
Mammary gland
Unclassified
Soft tissues
Gastrointestinal tract
Male sexual organs
Respiratory system, intrathoracic organs
Blood, haematopoietic system
Bones, joints, articular cartilage
Endocrine glands
Oral cavity, pharynx
Other female sexual organs
Urinary organs
Brain, meninges, other parts of the CNS
Lymph nodes
Retroperitoneum, peritoneum
Peripheral nerves, autonomic nervous system
Eyes, organs of perception
20
%
155
Fig. 6. Distribution of tumour locations diagnosed by post-
mortem investigation. n, number of post-mortem samples;
%, proportion of tumour location.
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Gamlem et al. (2008), 49% byMerlo et al. (2008) and
51% by Vascellari et al. (2009).
Skeletal tumours and melanomas showed the high-
est malignancy, with 96.61% and 87.21%, respec-
tively. These figures are also similar to the results
reported by Porello et al. (2006) and Ehrhart et al.
(2013). Skin (32.29%), the mammary gland
(20.53%) and soft tissues (11.90%) are the most
frequent tumour locations, as confirmed by
Dobberstein (1937), Mulligan (1949), Dorn (1967),
MacVean et al. (1978), Bastianello (1983), Arnesen
et al. (2001), Dobson et al. (2002), Gamlem et al.
(2008), Vascellari et al. (2009) and Dobson (2013).
These results are influenced by the fact that both loca-
tions are easy to access and to observe, both for the
dog owner and the veterinarian.
The ranking of the tumour locations diagnosed in
post-mortem investigations shows the highest values
for the gastrointestinal tract (14.23%) and the respi-
ratory system (10.63), including thoracic organs
(13.28%). In the ranking of all tumours sampled
through post-mortem and biopsy, the gastrointestinal
tract (7.49%) and the respiratory system, including
thoracic organs (2.09%), hold places 4 and 6, respec-
tively, similar to the observations of Dobson et al.
(2002), Porello et al. (2006), Vascellari et al. (2009)
Fig. 7. Tumour location and diagnoses. n, number of tumours found in a location;%, proportion of the location comparedwith the total of
locations. Figures in and around the slices show the relative proportion of tumour diagnoses/location. Tumour diagnoses<1%were
added into ‘other tumours’; locations<1%andunclassified locationswere not listed.With the exception of ‘male sexual organs’, the
listed locations are not sex specific.
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and Dobson (2013). The different frequencies in post-
mortem samples and samples from biopsy suggest an
over reporting of tumours at easily accessible loca-
tions, together with an underestimation of impene-
trable locations.
Themale sexual organs rank fifth (4.43%) in all ex-
amination methods and seventh (8.45%) in the post-
mortem samples. Both results demonstrate that differ-
ences depend on the method of investigation and are
similar to the findings of Dobberstein (1953),
Mulligan (1949), Dorn (1967) and Bastianello
(1983). Vascellari et al. (2009) observed that 13.4%
of tumours were found in the male genital tract. In
the Norwegian Canine Cancer Registry, tumours in
the testes (2.4%) were less frequent than in the oral
cavity (3.7%) (Gamlem et al., 2008), which is an
interesting difference in the distribution of these two
tumour locations compared with those in the Swiss
Canine Cancer Registry. Tumours of bones, joints
and joint cartilage were similar in ranking for all ex-
amination methods and post-mortem investigations,
with 1.82% and 4.84%, respectively. As previously
mentioned, the investigation method had a strong
impact on the distribution percentage. Gamlem
et al. (2008) described tumours of bones, joints and
joint cartilage as comparatively rare, with rates
<1.00%. Oral tumours accounted for 1.24% of all tu-
mours. Vascellari et al. (2009) found oral tumours
more than twice as frequently in dogs in Northern
Italy (2.6%) and Gamlem et al. (2008) found even
more such tumours in dogs in Norway (3.7%). This
discrepancymight be due to different sampling strate-
gies. In the Swiss Canine Cancer Registry post-
mortem data and biopsy samples were used, while
in the Italian and Norwegian data, biopsy samples
alone were used, where an overestimation of oral tu-
mours might be expected. In accordance with the
findings of Porello et al. (2006) and Thamm and
Dow (2009), oral tumours represented the highest
tumour type, including epithelial, lymphatic, mesen-
chymal, skeletal and odontogenic tumours and mela-
nomas. Further research on these tumours may offer
important insights for multimodality therapy in clin-
ical investigations. For the development of new ther-
apies it is advantageous that oral tumours develop
rapidly and cannot be controlled by surgery alone
(Porello et al., 2006).
Adenoma and adenocarcinoma were the most
frequent tumours in the Swiss Canine Cancer Regis-
try, in concordance with the Tulsa Registry
(MacVean et al., 1978). In the Danish Veterinary
Cancer Registry, the most frequently observed tu-
mours were lipoma and adenoma (Brønden et al.,
2010). Another study reported histiocytoma, lipoma
and adenoma as the most frequent tumours
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Fig. 8. Canine patients with none, one or several tumours per age.
n, number of patients.
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Fig. 10. Melanoma, gonadal neoplasia and skeletal tumours per
age of patient. n, number of tumour types per age.
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(Dobson, 2013). The assigned tumour groups, howev-
er, are not always consistent, so comparison provides
a rough overview only.
This study marks the beginning of a continuous
registration of dog tumours in Switzerland, which
will serve as reference for research in the fields of an-
imal and human oncology. To be able to compare re-
sults of different registries in the future it is important
that data collection is assimilated with other dog reg-
istries, as it is for human registries.
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CORRIGENDUM
Corrigendum to “The Swiss Canine Cancer
Registry: A Retrospective Study on the Occurrence
of Tumours in Dogs in Switzerland from 1955 to
2008” [ J Comp Pathol 152 (2e3) (2015) 161e171]
K. Gr€untzig*, R. Graf*, M. H€assig†, M. Welle‡, D. Meierx, G. Lott{,
D. Erni#, N. S. Schenker{, F. Guscetti{, G. Book, K. Axhausen††,*,
S. Fabrikantk, G. Folkers* and A. Pospischil{,*
*Collegium Helveticum, Universit€at Z€urich und Eidgen€ossische Technische Hochschule Z€urich (ETHZ), †Departement
Nutztiere Universit€at Z€urich, Z€urich, ‡Institut f€ur Tierpathologie Universit€at Bern, Bern, xZyto-Histo Diagnostics,
Freienstein, kGeographisches Institut, Universit€at Z€urich, {Institut f€ur Veterin€arpathologie Universit€at Z€urich, Z€urich,
#FocusedPublishing GmbH, CH-8332 Russikon and ††Institut f€ur Verkehrsplanung und Transportsysteme (IVT), ETHZ,
Z€urich, Switzerland
The authors regret to say that a mistake has been found in the above paper.
The 2nd line of Table 3 is on page 164 states incorrectly, “Adamantinoma of long bones”. The single diag-
nosis term should read “Adamantinoma of the jaw”. Please find a correct version of Table 3 below:
J. Comp. Path. 2015, Vol. 153, 64e65 Available online at www.sciencedirect.com
ScienceDirect
www.elsevier.com/locate/jcpa
Table 3
Example of tumour grouping for four selected groups
Diagnosis group Single diagnosis Number Percentage [%]
Skeletal tumour ICD-O
9180e9262
Adamantinoma of the jaw 103 8.7
Chondroblastoma 22 1.86
Chondroma, fibrochondrosarcoma 168 14.19
Osteochondroma 11 0.93
Osteofibroma 38 3.21
Osteoma, osteosarcoma 842 71.11
(Continued )
DOI of original article: http://dx.doi.org/10.1016/j.jcpa.2015.02.005.
Correspondence to: A. Pospischil (e-mail: apos@vetpath.uzh.ch).
0021-9975/$ - see front matter ! 2015 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.jcpa.2015.04.008
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This correction only applies to Table 3, the text of “Results” and “Discussion” is not affected.
The authors apologize for this error.
Table 3 (continued )
Diagnosis group Single diagnosis Number Percentage [%]
Total of skeletal tumours 1,184 100
Gonadal tumour ICD-O
8610e8670
Granulosa cell tumour, granulosa cell carcinoma 93 8.72
Leydig cell tumour 450 42.17
Luteoma 9 0.84
Sertoli cell adenoma, sertoli cell carcinoma 423 39.64
Sertoli-Leydig cell tumour 92 8.62
Total of gonadal tumours 1,067 100
Gonadal germ cell
tumour ICD-O
9060e9085
Embryonal carcinoma 3 0.45
Seminoma 632 95.47
Teratoma 8 1.21
Germ cell tumour 19 2.87
Total of gonadal germ cell tumours 662 100
Epithelial tumour ICD-
O 8010e8587, ICD-O
9050e9058
Adenocarcinoma of anal glands 2,421 9.27
Adenocarcinoma with squamous metaplasia 190 0.73
Adenoma, adenocarcinoma 12,348 47.27
Adenomatous polyp, adenocarcinoma in adenomatous polyp 321 1.23
Adrenal cortical adenoma, adrenal cortical adenocarcinoma 168 0.64
Basal cell carcinoma, adenoma 499 1.91
Carcinoma, anaplastic type 296 1.13
Cholangioma, cholangiocarcinoma 48 0.18
Composite carcinoid 43 0.16
Epithelial tumour ICD-O 8010e9053 1,677 6.42
Epithelioid mesothelioma 37 0.14
Epithelioma 958 3.67
Hepatoma, hepatocarcinoma 155 0.59
Insulinoma 52 0.2
Intracystic papillary adenoma, intracystic papillary adenocarcinoma 79 0.3
Intraductal papilloma, intraductal papillary carcinoma 12 0.05
Mesothelioma, biphasic, malignant 42 0.16
Multifocal superficial basal cell carcinoma 231 0.88
Papillary adenoma, adenocarcinoma 112 0.43
Papillary carcinoma 871 3.33
Pilomatrixoma 503 1.93
Pulmonary adenomatosis, bronchiolo-alveolar adenocarcinoma 45 0.17
Sebaceous adenoma, sebaceous adenocarcinoma 1,456 5.57
Secretory carcinoma of the mammary gland 329 1.26
Spindle cell carcinoma 72 0.28
Squamous cell carcinoma 1,324 5.07
Squamous papillomatosis 10 0.04
Sweat gland adenoma, sweat gland adenocarcinoma 427 1.63
Thymoma 96 0.37
Transitional cell papilloma, transitional cell carcinoma 168 0.64
Trichoepithelioma 1,132 4.33
Total of epithelial tumours 26,122 100
65
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Summary 
This study is based on the Swiss Canine Cancer Registry, comprising 121,963 diagnostic records of 
dogs compiled between 1955 and 2008, in which 63,214 (51.83%) animals were diagnosed with 
tumour lesions through microscopical investigation. Adenoma/adenocarcinoma (n = 12,293, 
18.09%) was the most frequent tumour diagnosis. Other common tumour diagnoses were: mast cell 
tumour (n = 4,415, 6.50%), lymphoma (n = 2,955, 4.35%), melanocytic tumours (n = 2,466, 
3.63%), fibroma/fibrosarcoma (n = 2,309, 3.40%), haemangioma/haemangiosarcoma (n = 1,904, 
2.80%), squamous cell carcinoma (n = 1,324, 1.95%) and osteoma/osteosarcoma (n = 842, 1.24%).  
The relative occurrence over time and the most common body locations of those tumour diagnoses 
is presented.  
Analyses of the influence of age, breed, body size, sex and neutering status on tumour development 
were carried out using multiple logistic regression. In certain breeds/breed categories the odds ratios 
for particular tumours were outstandingly high: the boxer had higher odds ratios for mast cell 
tumour and haemangioma/haemangiosarcoma, as did the shepherd group for 
haemangioma/haemangiosarcoma, the schnauzer for squamous cell carcinoma and the rottweiler for 
osteoma/osteosarcoma.  In small dogs, the risk of developing mammary tumours was three times 
higher than in large dogs. However, small dogs were less likely to be affected by many other tumour 
types (e.g. tumours of the skeletal system). 
 Examination of the influence of sex and neutering status on tumour prevalence showed that 
the results depend on the examination method. In all sampling groups the risk for female dogs of 
developing adenoma/adenocarcinoma was higher than for male dogs. Females had a lower risk of 
developing haemangioma/haemangiosarcoma and squamous cell carcinoma than males. Neutered 
animals were at higher risk of developing specific tumours outside the genital organs than intact 
animals. 
 
 The sample size allows detailed insight into the influences of age, breed, body size, sex and 
neutering status on canine tumour development. In many cases, the analysis confirms the findings of 
other authors. In some cases, the results are unique or contradict other studies, implying that further 
investigations are necessary. 
 
Keywords: cancer registry; dog; statistical analyses; tumour  
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Introduction 
To meet the challenge posed by the combination of potential aetiological factors in cancer, 
patient data and diagnoses need to be explored systematically (MacVean et al., 1978; Brønden et 
al., 2007, 2010; Vascellari et al., 2009; Dobson, 2013; Waters et al., 2014). This is the 
cornerstone of any epidemiological study of cancer that aims to investigate cancer development 
patterns in defined populations over time and space. The epidemiological study of cancer is 
therefore dependent on the availability of patient data that are usually stored in cancer registries. 
In this context, the study of companion animal cancer registries is especially valuable. 
Firstly, companion animals and their owners share the same environment and are therefore mostly 
exposed to the same environmental cancer risk factors (Bukowski and Wartenberg, 1997; Backer 
et al., 2001; Gamlem et al., 2008; Marconato et al., 2009; Bettini et al., 2010). Secondly, similar 
genetic predisposing factors for cancer development have been found for man and animals 
(Jónasdóttir et al., 2000; Patterson, 2000;  Lingaas et al., 2003; Breen, 2009; Pastor et al., 2009; 
Phillips et al., 2010; Ke et al., 2011).  For instance, canine renal cystadenocarcinoma and nodular 
dermatofibrosis (Jónasdóttir et al., 2000; Lingaas et al., 2003) and canine osteosarcoma (Phillips et 
al., 2010) are well-known examples of syndromes linked to genetic conditions common to both 
dogs and man. The former complex was linked to a specific mutation also found in people affected 
by a similar syndrome; in the latter a linkage to a specific locus was found in both species. These 
findings underline the value of comparative studies in human and veterinary oncology as part of 
the ‘One Health’ concept (Breen, 2009). 
The present study is based on the Swiss Canine Cancer Registry (Grüntzig et al., 2015) 
and highlights the influences of age, breed, body size, sex and neutering status on the 
development of tumours in dogs. The size of the Swiss Canine Cancer Registry, which comprises 
121,963 dogs and 67,943 tumour diagnoses, allows computation of meaningful statistics. To our 
knowledge, the Swiss Canine Cancer Registry is the most comprehensive animal cancer registry 
at a national level. 
 
Materials and Methods 
 
Data Source 
The data originated from the Swiss Canine Cancer Registry (Grüntzig et al., 2015) comprising 
121,963 diagnostic records of dogs provided by three veterinary diagnostic laboratories in 
Switzerland: the Vetsuisse Faculty Institut für Veterinärpathologie, Zürich (IVPZ), the Vetsuisse 
Faculty Institut für Tierpathologie, Bern (ITPA) and the Zyto/Histo Diagnostik private veterinary 
diagnostic laboratory (based in Rorbas Freienstein). The data sets included diagnostic records 
from canine samples generated by three different examination methods: post-mortem analysis 
(and subsequent histopathological evaluation), biopsy sampling (with subsequent 
histopathological examination) and cytology. Biopsy and cytology samples are hereafter called 
ex-vivo samples. No cases were excluded; however, some parameters were missing due to 
incomplete reporting by the submitting veterinarians.  All diagnoses in the Swiss Canine Cancer 
Registry were derived from a microscopical examination. 
 
Data Preparation 
In different time periods, different terms were used for the description of age, breed, sex and 
neutering status. Those differences were standardized by numerical coding. The diagnoses were 
then coded according to the tumour topographical and morphological keys of the ICD-O-3 (Fritz 
et al., 2013) and checked for plausibility using the original patient records. All tumour diagnoses 
were based on either histopathological or cytological examination.  Epidermal cysts were 
excluded.  
The data included 215 castrated male dogs with tumours in the testes. Since it is common 
in those cases to castrate the patient while sampling the tumour, those dogs where re-classified as 
entire at the moment of tumour diagnosis. 
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Data sets missing the information on the sex and/or status of neutering of patients were 
excluded from the evaluation of the influence of these parameters on tumour development. 
Breed allocation was based on information available in the diagnostic records, which was 
usually provided by the pet owner or by the submitting veterinarian. A declaration of one breed 
was accepted as reported, while a declaration comprising two breeds (in the case of an apparent 
mix with recognizable breeds) was categorized according to the breed mentioned first (i.e. a 
shepherd-cross was categorized under shepherd, a shepherd–boxer-cross likewise under 
shepherd, and a boxer–shepherd-cross under boxer).  It was assumed that the breed mentioned 
first was the one more obvious from the external appearance. Therefore the breeds defined in this 
work cannot be considered pure breeds and a certain influence of mixed breeding must be 
acknowledged in the risk calculations. The proportion of manifestly non-pure breeds ranged 
between 0 and 18% in the breeds considered for analysis (Table 1).  Because all such mixed 
breeds likely share at least 50% of their genetic information with the predominant breed, the 
content of non-breed related genome is maximally half in these animals. This should be taken 
into account while interpreting the results of the statistics. As an example, for the Swiss mountain 
dog, the breed with the highest proportion of manifestly crossed individuals (18.14%), the 
unrelated genome may theoretically account for a difference of 9% in the odds ratio. 
A non-specific allocation such as mixed-breed, mongrel or crossbreed was categorized 
under crossbreed, since it was assumed that a phenotype typical for a known breed was lacking or 
not distinct.  
The breeds/breed categories most frequently represented in the data set, each comprising 
at least 900 individuals, were retained for the analysis of risks related to breed (Table 1). In a 
preliminary investigation the breed ranking of the data set and the breed ranking of the Swiss dog 
population was compared in those years in which a reference population with known breed 
composition was available for use as a control (1963, 1999 and 2008) (Pospischil et al., 2013).  
For those years the patient breed ranking correlated with that of the reference population, 
meaning that there was no significant difference in breed distribution between the Swiss dog 
population and the patient collective. The difference in the distribution of the individual breeds 
over time was controlled for year and proportional distribution. 
The remaining breeds and the diagnostic records with unknown breeds were listed as 
‘other breeds’. The breed category Swiss mountain dog includes Appenzeller mountain dogs, 
Bernese mountain dogs, Entlebucher mountain dogs, large Swiss mountain dogs, Swiss mountain 
dogs and mountain dogs. The breed category retriever includes Chesapeake Bay retriever, curly 
coated retriever, flat coated retriever, golden retriever, Labrador, Nova Scotia duck tolling 
retriever, retriever and sandriner (golden retriever crossed with Irish setter). The breed category 
setter includes English setter, Gordon setter, Irish red and white setter, Irish red setter, Irish setter 
and setter. The breed category shepherd includes German shepherd dog, Beauceron Berger de 
Beauce, white shepherd, Berger de Picardie, Berger de Savoie, Berger des Pyrénées, 
Groenendael, Laekenois, Malinois and Tervueren. 
For the examination of the influence of body size on tumour development two groups 
were established. ‘Large breeds’ comprised the doberman, great Dane, retriever, rottweiler, Swiss 
mountain dogs, shepherd and setter. ‘Small breeds’ comprised the bulldog, dachshund, Parson 
Jack Russell, West Highland white terrier and Yorkshire terrier. 
 
Statistical Evaluation 
Data editing and statistical analyses were performed using Stata Software (Stata Corp., 2011; 
Stata Statistical Software: Release 12; College Station, Texas, USA). Statistical analyses were 
carried out using a Chi-Square/Fisher’s exact test. Significant univariable variables were further 
integrated in a multiple logistic regression model using binary logistic models and stepwise 
backward procedure. The following variables were included in the model as fixed terms: sex, 
neutering status, breed, age, year, method of examination and canton of origin. The first four 
variables are random variables related to the animals and were also used for the specific 
evaluations on cancer frequency. The three latter variables were random factors related to time, 
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examination method and spatial distribution. The underlying Stata model for the multiple logistic 
regression was <logistic vary varx1 varx2 varx3 varx4 varx5 varx6 varx7>, whereby vary = 
tumour, varx1 = sex, varx2 = neutering status, varx3 = breed, varx4= age, varx5= year of 
examination, varx6= method of examination, varx7= canton of origin.  P <0.05 was considered to 
be significant and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. The 
power was set at 0.8. In the statistical evaluation, crossbreeds were used as the standard for 
comparisons with the remaining breeds, since they were assumed to have the largest genetic 
variation. For the evaluation of influence of sex and neutering status (Fig. 6) on overall tumour 
development, the data were divided into two subsets based on the examination method: post-
mortem samples and ex-vivo samples.  The results of the following three groups were compared: 
post-mortem samples, ex-vivo samples and all samples. For the evaluation of the influence of sex 
and neutering status on most common tumour diagnoses and locations (Tables 2–4), the total data 
set (all samples) was compared with the post-mortem sample data subset. The analyses of the 
influence of age on specific tumour development was biased by the low number of cases aged 
>15 years. Therefore results are shown until the age of 15.  
 
Results 
The Swiss Canine Cancer Registry consists of records from 126,693 dogs that underwent 
pathological examination. The number of patients with confirmed tumours was 63,214 (51.83%).  
Some dogs were diagnosed with multiple primary tumours, adding up to a total of 67,943 
diagnosed tumour lesions. 
The age distribution has been previously presented (Grüntzig et al., 2015). A large number 
of the dogs were crossbred (n = 12,193; 10.00%). Breed distribution is given in Table 1. The 
collective comprised 56,062 (45.97%) male dogs and 61,754 (50.63%) female dogs. The neutering 
status was recorded as entire in 59,902 (49.11%) dogs, neutered in 26,127 (21.42%) dogs (8,845 
male, 17,731 female) and not specified in 35,934 (29.46%) dogs. 
The following results show the influence of breed on the most common tumour types, as 
well as of age, body size, sex and neutering status on the overall and specific tumour occurrence.  
In addition, the influence of sex and neutering status on the anatomical locations is reported. Their 
occurrence patterns over the years are also included. The classification and distribution of the 
tumour species of the data set is presented in Supplementary Table 1. 
 
Table 1 Frequencies of the 17 most common breeds/breed categories in the registry and their 
relative proportions of crossbreeds and ensuing proportion of unrelated genome. 
Breed/breed 
category 
Total number*   Thereof manifestly crossed Unrelated 
genome 
Shepherd 12,354 (10.13%) 867 (7.02%) 3.51% 
Crossbreed 12,193 (10.00%) 12,193 (100%) n.s. 
Retriever 11,429 (9.37%) 802 (7.02%) 3.51% 
Swiss Mountain 
Dog 7,774 (6.37%) 1,410 (18.14%) 9.07% 
Poodle 7,214 (5.91%) 173 (2.40%) 1.20% 
Dachshund 6,499 (5.33%) 189 (2.91%) 1.46% 
Boxer 6,368 (5.22%) 127 (1.99%) 0.99% 
Schnauzer 2,796 (2.29%) 156 (5.58%) 2.79% 
Collie 2,206 (1.81%) 223 (10.11%) 5.06% 
Yorkshire Terrier 2,157 (1.77%) 7 (0.32%) 0.16% 
Cocker Spaniel 2,127 (1.74%) 19 (0.89%) 0.45% 
Setter 2,105 (1.73%) 105 (4.99%) 2.49% 
Great Dane 1,598 (1.31%) 44 (2.75%) 1.38% 
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Doberman Pinscher 1,596 (1.31%) 72 (4.51%) 2.26% 
Rottweiler 1,470 (1.21%) 63 (4.29%) 2.15% 
West Highland 
White  Terrier 1,316 (1.08%) 3 (0.23%) 0.12% 
Bulldog 1,016 (0.83%) 0 (0.00%) 0.00% 
Parson Jack Russell 
Terrier 981 (0.80%) 75 (7.65%) 3.83% 
Other breeds 
(including dogs of 
unknown breeds) 
38,764 (31.78%) n.s. n.s. n.s. 
Total of all breeds 121,963 (100%) 16,528 (13.55%)  7.78% 
 
* Dogs were allocated to a certain breed based on the owner's claims; crossbreeds with dominant traits of a breed were 
included 
 n.s.: not specified 
 
 
Adenoma/Adenocarcinoma (ICD –O 8140) 
Adenomas/adenocarcinomas (n = 12,293, 18.09%) were the most common tumour diagnosed 
overall. From 1955 to 1985, approximately 30 to 40% of the diagnosed tumours were 
adenomas/adenocarcinomas. After 1985, the frequency of these diagnoses progressively dropped 
to 12% in 2008 (Fig. 1). Adenomas/adenocarcinomas were most commonly diagnosed in the 
mammary gland (n = 6,805; 55.36%) and in the gastrointestinal tract (n = 1,020; 8.30%).  Using 
multiple regression analysis, the odds ratios of the dog breeds/breed categories developing an 
adenoma/adenocarcinoma were compared with those of the crossbreds (OR = 1).  The Yorkshire 
terrier, the poodle, the cocker spaniel, the collie, the dachshund and the West Highland white 
terrier presented with significantly higher odds ratios in comparison with Crossbreds and the other 
breeds/breed categories included in the analysis.  Breeds/breed categories with lower odds ratios 
were the rottweiler, the great Dane, the bulldog, the retriever, the doberman, the schnauzer, the 
Swiss mountain dog, the setter, the boxer and the shepherd (Fig. 2). 
 
Mast Cell Tumours (ICD-O 9740) 
Among the 67,943 neoplasms, 4,415 (6.50%) were diagnosed as a mast cell tumour. Between 1955 
and 2008 the relative frequency of mast cell tumours rose with considerable fluctuations from 
2.1% to 8.4% of the overall tumour diagnoses (Fig. 1). Mast cell tumours (n = 4,415) were mainly 
diagnosed in the skin (n = 4,324; 97.94%).  The boxer showed outstanding significantly higher 
odds ratios of developing a mast cell tumour in comparison with crossbreds and to the other 
breeds/breed categories.  Other breeds with higher risk were the Swiss mountain dogs, the retriever 
and the bulldog.  Breeds/breed categories with lower odds ratios were the collie, the rottweiler, the 
West Highland white terrier, the shepherd, the poodle, the Yorkshire terrier, the cocker spaniel, the 
doberman and the dachshund (Fig. 2). 
 
Lymphoma (ICD-O 9590, 9591, 9700) 
Among the 67,943 diagnosed tumours, 2,955 (4.35%) were lymphomas.  Between 1955 and 2008 
the relative frequency of lymphoma decreased from 6.52% to 3.97% per year and from 1968 to 
1988 it was around 2% (Fig. 1).  Lymphomas (n = 2,955) were most commonly diagnosed in the 
lymph nodes (n = 1,362; 46.09%) and in unspecified locations (n = 425; 14.38%), followed by the 
blood and haemopoietic system (n = 380; 12.86%), skin (n = 234; 7.92%), the spleen (n = 206; 
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6.97%) and the liver (n = 69; 2.34%). Logistic regression revealed that the rottweiler has a 
markedly higher odds ratio of developing a lymphoma than crossbreds and other breeds/breed 
categories included in the analysis. Another breed category with higher odds ratios was the Swiss 
mountain dog. The poodle, the Yorkshire terrier, the dachshund, the retriever and the shepherd had 
lower odds ratios for lymphoma (Fig. 2).  
 
Melanocytic Tumours (ICD-O 8720, 8730) 
Among the 67,943 neoplasms diagnosed, 2,466 (3.63%) were melanocytic tumours. From 1955 to 
2008 the relative frequency of melanocytic tumours rose from under 2% to over 4% (Fig. 1). The 
most common anatomical locations for melanocytic tumours (n = 2,466) were the skin (n = 2,309; 
93.6%) and the oral cavity/nasopharynx (n = 106; 4.3%). Multiple regression analysis revealed that 
the odds ratios for the following dog breeds/breed categories of developing a melanocytic tumour 
were higher than those of crossbreds and the other breeds/breed categories included in the analysis: 
the setter, the schnauzer, the rottweiler, the retriever, the poodle, the doberman, the dachshund and 
the cocker spaniel. The bulldog, the West Highland white terrier, the collie, the boxer and the 
Great Dane presented with lower odds ratios for melanocytic tumours (Fig. 2). 
 
Fibroma/Fibrosarcoma (ICD-O 8810, 8812) 
Among the 67,943 tumours, 2,309 (3.40%) were diagnosed as a fibroma/fibrosarcoma. Between 
1960 and 1996 the relative frequency of fibroma/fibrosarcoma increased with several fluctuations 
from 1.16% to 6.71% of the total tumour number. From 1996 to 2008 their relative frequency was 
between 2.10% and 3.56%. (Fig. 1). The most common anatomical locations for 
fibroma/fibrosarcoma (n = 2,309) were the soft tissues (n = 1,080; 46.77%) and the skin (n = 
1,040; 45.04%). The setter, the Swiss mountain dog, the rottweiler, the retriever, the doberman and 
the boxer had higher odds ratios of developing fibroma/fibrosarcoma than did crossbreds and the 
other breeds/breed categories included in the analysis. The West Highland white terrier, the 
Yorkshire terrier, the dachshund and the poodle presented with lower odds ratios for 
fibroma/fibrosarcoma (Fig. 2). 
 
Haemangioma/Haemangiosarcoma (ICD-O 9120, 9121) 
Among the 67,943 diagnosed tumours, 1,904 (2.80%) were a haemangioma/haemangiosarcoma.  
Between 1955 and 2008 the relative frequency of these tumours rose from 0 to 3.45%, reaching a 
peak of 7.92% in 1996 (Fig. 1). The most common anatomical locations for 
haemangioma/haemangiosarcoma (n = 1,904) were soft tissues (n = 1,203, 63.18%) and the skin (n 
= 459; 24.11%), followed by the blood/haemopoietic system (n = 113; 5.93%). The shepherd (OR 
1.806 [CI = 1.518, 2.150]) and the boxer (OR 1.850 [CI = 1.506, 2.261]) showed higher odds 
ratios of developing a haemangioma/haemangiosarcoma than crossbreds and the other 
breeds/breed categories included in the analysis. The West Highland white terrier, the Yorkshire 
terrier, the rottweiler, the poodle, the doberman, the great Dane, the cocker spaniel, the bulldog, 
and the dachshund presented with lower odds ratios for haemangioma/haemangiosarcoma (Fig. 2). 
 
Squamous Cell Carcinoma (ICD-O 8070, 8071, 8078)  
Among the 67,943 tumours, 1,324 (1.95%) were diagnosed as a squamous cell carcinoma. After a 
peak of 7.46% in 1958 the relative frequency of squamous cell carcinoma fluctuated between 
0.94% and 4.02% of the overall tumour diagnoses until 1999. From 2000 to 2008 it was between 
1.47% and 2.29% (Fig. 1). The high numbers in the 1950s might result from a bias due to the low 
amount of tumour data available from this period. The most common anatomical locations for 
squamous cell carcinoma (n = 1,324) were unspecified locations (n = 615; 46.5%), the skin (n = 
601; 45.4%) and the oral cavity/nasopharynx (n = 56; 4.23%). Here, results for the schnauzer 
revealed a seven-fold higher risk (OR 7.712 [CI = 6.031, 9.860]) of developing a squamous cell 
carcinoma than the other breeds/breed categories included in the analysis. The boxer presented 
with a lower odds ratio for squamous cell carcinoma (Fig. 2). 
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Osteoma/Osteosarcoma (ICD-O 9180)  
Among the 67,943 tumours, 842 (1.24%) were diagnosed as an osteoma/osteosarcoma. From 1955 
to the late 1960s the relative frequency of osteoma/osteosarcoma was variable, ranging between 
6% and 0% of the overall tumour diagnoses. In the 1970s and 1980s it was constantly under 1%. 
Up to 2008 it rose to 1.56%, with two peaks over 2% in the 1990s (Fig. 1). The most common 
anatomical locations for osteoma/osteosarcoma were bones and joints (n = 746; 88.60%), followed 
by skin (n = 26; 3.08%). The rottweiler (OR 3.321 [CI = 2.321, 4.752]) and the great Dane (OR 
1.936 [CI = 1.248, 3.003]) presented with a higher risk of developing an osteoma/osteosarcoma 
than crossbreds and the other breeds/breed categories included in the analysis. The bulldog, the 
dachshund, the West Highland white terrier, the Parson Jack Russell terrier, the Yorkshire terrier, 
the poodle, the cocker spaniel and the schnauzer presented with lower odds ratios for 
osteoma/osteosarcoma (Fig. 2). 
 
 
Fig. 1. Relative tumour frequencies between 1955 and 2008. 
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Fig. 2.  Odds ratios (ORs) and 95% confidence intervals (CIs) for the most common dog 
breeds/breed categories of developing specific tumours compared with those for crossbreds (OR = 
1). The number of observations was 126,692. 
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Influence of Age on Overall Tumour Development 
Analyses of the influence of age revealed that the risk of developing adenoma/adenocarcinoma, 
melanocytic tumours and squamous cell carcinoma increased almost constantly with age. The risk 
of developing mast cell tumours, fibroma/fibrosarcoma, haemangioma/haemangiosarcoma and 
osteoma/osteosarcoma was only moderately influenced by increasing age after the age of 3, 4, 5 
and 6 years, respectively. The risk of developing a lymphoma increased constantly with age until 6 
years and decreased thereafter (Figs. 3, 4). 
 
Fig. 3. Odds ratios (ORs) and 95% confidence intervals (CIs) for patients at different ages of 
developing different tumour types compared with patients aged <1 year (OR = 1). The number of 
observations was: 126,692 for adenoma/adenocarcinoma and 126,665 for lymphoma. 
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Fig. 4.  Odds ratios (ORs) and 95% confidence intervals (CIs) for patients at different ages of 
developing different tumour types compared with patients aged <1 year (OR = 1). The number of 
observations was: 126,682 for mast cell tumour, 126,665 for fibroma/fibrosarcoma, 126,411 for 
osteoma/osteosarcoma; 126,593 for haemangioma/haemangiosarcoma; 126,651 for melanocytic 
tumours and 126,665 for squamous cell carcinoma. 
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(OR 1.305 [CI = 1.223, 1.392]), setter (OR 1.299 [CI = 1.179, 1.431]), schnauzer (OR 1.289 [CI 
= 1.182, 1.405]) and retriever (OR 1.278 [CI = 1.211, 1.348]) were at higher risk of developing a 
tumour than were crossbreds.  Great Dane (OR 0.532 [CI = 0.475, 0.596]), bulldog (OR 0.615 
[CI = 0.537, 0.704]), West Highland white terrier (OR 0.701 [CI = 0.622, 0.789]), Parson Jack 
Russell terrier (OR 0.791 [CI = 0.690, 0.906]), rottweiler (OR 0.829 [CI = 0.739, 0.929]), 
doberman (OR 0.833 [CI = 0.747, 0.929]), collie (OR 0.840 [CI = 0.764, 0.923]), shepherd (OR 
0.872 [CI = 0.827, 0.919]) and Yorkshire terrier (OR 0.897 [CI = 0.816, 0.986]) were at lower 
risk of developing a tumour than crossbreds (Fig. 5). There was no generally higher risk for 
defined breeds/breed categories as a whole group compared with mixed breeds. 
 
 
Fig. 5.  Odds ratio (OR) for defined breeds/breed categories of developing a tumour compared with 
crossbreds. The number of observations was 126,692. 
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tumour of the endocrine glands (OR 1.548 [CI = 1.190, 2.014]) than the large breed group. Small 
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cartilage (OR 0.192 [CI = 0.131, 0.282]). 
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14.20% lower (OR 0.858 [CI = 0.823, 0.894]) for neutered females than for entire females (Fig. 
6). 
 
Fig. 6. Odds ratios (OR) of developing a tumour by sex and castration status, subclassified by 
examination method. The number of observations was: 1 35,649; 2 7,357; 3 43,006; 4 40,243; 5 
6,144; 6 46,387; 7 95,746; 8 26,733; 9 122,479. 
 
Influence of Sex and Neutering Status on Specific Tumour Development 
Hereafter, only results significant in both investigated groups (i.e. the total data set and the subset 
of post-mortem samples) are reported. All results are presented in Tables 2–5. The distribution of 
tumour locations for the investigated groups is presented in Supplementary Tables 2–5. 
The odds ratios for female dogs of developing an adenoma/adenocarcinoma were 
significantly higher than those for male dogs. Females presented with lower odds ratios for 
haemangioma/haemangiosarcoma and squamous cell carcinoma than males (Table 2). 
Neutered male dogs presented with higher odds ratios of developing the following tumours 
than entire male dogs: adenoma/adenocarcinoma, lymphoma, mast cell tumour and 
osteoma/osteosarcoma (Table 3). 
Neutered female dogs had lower odds ratios of developing adenoma/adenocarcinoma than 
entire females. Neutered female dogs presented with higher odds ratios for the following tumours: 
haemangioma/haemangiosarcoma, lymphoma, mast cell tumour and melanocytic tumour (Table 
3). 
 
Influence of Sex and Neutering Status on Tumour Location  
Female dogs presented with higher odds ratios of developing mammary gland tumours than male 
dogs (Table 4).  
Neutered male dogs presented with higher odds ratios for skin tumours, tumours of the 
blood and the hemopoietic system, tumours of the endocrine glands, the respiratory system and 
intrathoracic organs and unspecified locations than entire male dogs (Table 5). 
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Neutered female dogs presented with higher odds ratios for skin and soft tissue tumours, 
tumours of the blood and the hemopoietic system, the gastrointestinal tract, the oral cavity and 
pharynx, the respiratory system and intrathoracic organs and the urinary organs than entire 
female dogs. They had lower odds ratios for tumours of the mammary gland (Table 5). 
To verify the results above, the investigations for neutered females versus entire females 
were repeated, excluding tumours of the mammary gland. The deviations from the results that 
included mammary gland tumours were negligible (Supplementary Tables 6–7). An exception 
was the result for adenoma/adenocarcinoma in post-mortem samples: neutered females had a 
higher risk for adenoma/adenocarcinoma than entire females when mammary tumours were 
excluded. 
 
 
 
 
Table 2 Risk of developing the most common tumour types, comparing sexes and sampling 
methods. Statistically significant results are in bold. The number of observations was: 1 
126,692; 2 27,753 
 
 Odds ratios and [95% confidence intervals] for 
females compared to males (OR=1) in samples 
collected with  
Tumour type all methods 1 post mortem 2 
Adenoma, adenocarcinoma 1.337 [1.318, 1.356] 1.106 [1.075, 1.137] 
Fibroma, fibrosarcoma 0.904 [0.878, 0.930] 1.081 [0.966, 1.211] 
Hemangioma, 
hemangiosarcoma 
0.889 [0.862, 0.917] 0.908 [0.842, 0.979] 
Lymphoma 0.953 [0.929, 0.977] 0.968 [0.926, 1.011] 
Mast cell tumour 1.005 [0.984, 1.026] 0.982 [0.874, 1.103] 
Melanocytic tumour 0.843 [0.820, 0.867] 0.969 [0.843, 1.115] 
Osteoma, osteosarcoma 1.004 [0.959, 1.052] 1.031 [0.949, 1.121] 
Squamous cell carcinoma  0.888 [0.856, 0.922] 0.784 [0.686, 0.896] 
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Table 3 Risk of developing the most common tumour types, comparing castration status and 
sampling methods. Statistically significant results are in bold. The number of observations 
was: 1 43,006; 2 7,357; 3 46,387; 4 6,144 
 Neutered males compared to intact males 
(OR=1) 
Neutered females compared to intact females 
(OR=1) 
 in ex vivo and post 
mortem samples1 
in post mortem 
samples2 
 in ex vivo and post 
mortem samples3 
 in post mortem 
samples4 
Tumour type OR & [95%CI] OR & [95%CI] OR & [95%CI] OR & [95%CI] 
Adenoma, 
adenocarcinoma 
1.384 [1.218, 1.573] 1.730 [1.339, 2.237] 0.650 [0.604, 0.699] 1.183 [0.967, 1.446] 
Fibroma, 
fibrosarcoma 
1.181 [0.984, 1.417] 0.824 [0.361, 1.880] 1.183 [1.010, 1.386] 1.128 [0.559, 2.276] 
Hemangioma, 
hemangiosarcoma 
0.995 [0.832, 1.188] 1.005 [0.665, 1.519] 1.610 [1.374, 1.886] 2.438 [1.606, 3.703] 
Lymphoma 1.150 [1.006, 1.315] 1.558 [1.130, 2.150] 1.349 [1.194, 1.525] 2.295 [1.694, 3.111] 
Mast cell tumour 1.150 [1.008, 1.313] 3.461 [1.515, 7.910] 1.190 [1.080, 1.312] 2.980 [1.355, 6.551] 
Melanocytic tumour 0.962 [0.817, 1.133] 0.868 [0.251, 3.002] 1.407 [1.216, 1.627] 4.425 [1.619, 12.094] 
Osteoma, 
osteosarcoma 
1.555 [1.218, 1.985] 2.022 [1.151, 3.554] 1.210 [0.982, 1.491] 1.420 [0.887, 2.275] 
Squamous cell 
carcinoma  
0.771 [0.588, 1.010] 3.811 [1.515, 9.585] 1.287 [1.051, 1.576] 1.969 [0.502, 7.719] 
 
Table 4 Risk of developing a tumour in the most common locations, comparing sexes and 
sampling methods. Significant results in bold. The number of observations was: 1 126,692; 2 
27,753 
 
Females compared to males (OR=1) 
 
in ex vivo and post mortem 
samples1 in post mortem samples2 
Tumour location OR & [95%CI] OR & [95%CI] 
Skin 0.895 [0.886, 0.905] 0.964 [0.902, 1.029] 
Mammary gland  3.264 [3.163, 3.369] 4.115 [3.486, 4.858] 
Soft tissues  1.027 [1.011, 1.043] 0.930 [0.886, 0.975] 
Blood, hematopoietic system  0.912 [0.880, 0.946] 0.982 [0.930, 1.038] 
Neoplasia of bones, joints, 
cartilage  0.975 [0.936, 1.016] 0.961 [0.892, 1.035] 
Endocrine gland  0.996 [0.951, 1.043] 1.089 [1.032, 1.15] 
Gastrointestinal tract  0.741 [0.726, 0.756] 1.005 [0.962, 1.050] 
Lymph nodes  0.923 [0.852, 0.999] 0.942 [0.837, 1.060] 
Oral cavity, pharynx  0.954 [0.911, 0.999] 0.964 [0.846, 1.097] 
Respiratory system, 
intrathoracic organs  0.948 [0.914, 0.982] 1.024 [0.979, 1.071] 
Urinary organs  1.034 [0.965, 1.108] 1.059 [0.951, 1.178] 
Unspecified location 1.032 [1.016, 1.047] 0.968 [0.936, 1.001] 
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Table 5 Risk of developing a tumour in the most common locations, comparing castration 
status and sampling methods. Significant results are in bold. The number of observations was: 
1 43,006; 2 7,357; 3 46,387; 4 6,144. 
 
Neutered males vs. intact males (OR=1) Neutered females vs. intact females (OR=1) 
 
in ex vivo and post 
mortem samples1 
in post mortem 
samples2 
in ex vivo and post 
mortem samples3 in post mortem samples4 
Tumour location OR & [95%CI] OR & [95%CI] OR & [95%CI] OR & [95%CI] 
Skin 1.088 [1.020, 1.161] 2.303 [1.473, 3.601] 1.208 [1.146, 1.274] 2.226 [1.637, 3.028] 
Mammary gland  1.099 [0.842, 1.434] 0.639 [0.077, 5.317] 0.411 [0.383, 0.440] 0.574 [0.408, 0.806] 
Soft tissues  1.352 [1.247, 1.466] 1.169 [0.843, 1.621] 1.278 [1.196, 1.366] 2.226 [1.637, 3.028] 
Blood, hematopoietic 
system  1.385 [1.069, 1.795] 1.974 [1.248, 3.123] 1.549 [1.208, 1.986] 1.970 [1.251, 3.102] 
Bones, joints, cartilage  1.492 [1.203, 1.850] 1.475 [0.881, 2.470] 1.258 [1.043, 1.517] 1.136 [0.714, 1.807] 
Endocrine gland  1.563 [1.159, 2.106] 1.705 [1.155, 2.516] 1.262 [0.965, 1.650] 1.101 [0.790, 1.535] 
Gastrointestinal tract  1.124 [0.999, 1.265] 1.579 [1.178, 2.118] 1.472 [1.296, 1.672] 1.975 [1.524, 2.558] 
Lymph nodes  1.551 [1.000, 2.408] 2.318 [1.035, 5.195] 1.105 [0.719, 1.700] 1.137 [0.465, 2.778] 
Other male sexual organs 
(penis, prostate gland, 
scrotum)  1.279 [0.875, 1.870] 1.729 [0.990,3.020] no observations no observations 
Other female sexual 
organs (vagina, uterus, 
ovary) no observations no observations 1.012 [0.747, 1.370] 0.332 [0.127, 0.870] 
Oral cavity, pharynx  1.267 [0.998, 1.608] 0.358 [0.085, 1.517] 1.348 [1.094, 1.661] 4.733 [2.009, 11.152] 
Respiratory system, 
intrathoracic organs  1.498 [1.176, 1.909] 1.738 [1.306, 2.313] 1.554 [1.271, 1.900] 1.784 [1.402, 2.271] 
Urinary organs  1.419 [0.894, 2.251] 1.837 [0.947, 3.566] 1.695 [1.203, 2.388] 2.656 [1.565, 4.508] 
Unspecified location 1.133 [1.042, 1.233] 1.649 [1.275, 2.132] 1.005 [0.939, 1.075] 1.803 [1.441, 2.254] 
 
 
Discussion 
The exceptionally large data set of the Swiss Canine Cancer Registry allowed multiple logistic 
regression, which was not always possible in the case of other registries and renders comparisons 
difficult. However, the datasets may be biased over time and further confounders could 
substantially influence the results. To overcome such influences specifically and to raise 
sensitivity, more general diagnostic terms were used. Further obstacles to comparison are typical 
issues related to the reproducibility of diagnoses in pathology, due to criteria for certain 
diagnoses changing over time and to the clearly subjective factor in histopathological diagnoses 
(Brønden et al., 2007; Pospischil and Folkers, 2015). In this study, the influence of different time 
periods on techniques and state of the art in tumour diagnoses was taken into account by 
including the year of diagnosis as a variable in the statistical evaluation. 
For the sake of simplicity only findings determined to be significant in the present work 
will be discussed below, while discussion of previously described results not confirmed by the 
present analysis will be omitted. 
Adenoma/adenocarcinoma was the most frequent tumour diagnosis in dogs. Its relative 
proportion in total tumour diagnoses dropped from 40.6% in 1980 to 12.3% in 2008. In 1980, 
92.80% of all examined canine patients (n = 2,194) were entire. However, the relative proportion 
 32 
of entire animals decreased to 55.6% of total patients (n = 7,879) in 2008.  Since over 60% of the 
adenomas/adenocarcinomas were found in the sexual organs, the increasing tendency to neuter 
dogs could be one reason for the decrease in relative frequency of adenoma/adenocarcinoma. A 
similar tendency was observed for canine mammary cancers in Italy by Merlo et al. (2008). 
Another aspect is the refinement in diagnostics over time, leading to a broader diversity of tumour 
diagnoses. 
The relative frequency of mast cell tumours, melanocytic tumours and 
haemangioma/haemangiosarcoma rose fairly constantly from 1955 to 2008. Since neutered female 
dogs are more frequently affected by these tumour types, the increase in neutering frequency over 
time might be partly responsible for this development.  
Vascellari et al. (2009) reported a frequency of 3% for canine lymphomas in the animal 
tumour registry of two provinces in Northern Italy between 2005 and 2008, which is comparable 
with our data (4.88% lymphomas). 
The relative frequency of fibroma/fibrosarcoma increased from 6.52% in 1955 to 10.76% 
in 1996 and decreased to 5.41% in 2008. These results are in contrast with the increase in feline 
fibroma/fibrosarcoma (20%) observed in Switzerland in the 1990s (Graf et al., 2016).  However, 
in cats a strong connection between vaccination and the development of sarcomas at sites of 
injection is under discussion (Henry, 2013). Such a connection has not been observed 
consistently in dogs. 
The peaks in the relative frequency of tumour types between 1996 and 1999 were due to 
very high numbers of the respective tumours in the data sent in by the Vetsuisse Faculty Institut 
für Tierpathologie, Bern (ITPA). It is likely that these sudden increases were artificially 
generated by tumour studies in the institute. This is an example of factors that can skew tumour 
frequencies in the present study setting. 
It is a well-known fact that overall tumour risk increases with age. In our data this was 
confirmed for adenoma/adenocarcinoma, melanocytic tumours and squamous cell carcinoma.  
Interestingly, the following tumour types in our study showed a frequency pattern deviating from 
that described above. The lymphoma risk peaked at 6 years of age. This finding is comparable 
with results of an Italian study (Merlo et al., 2008) but contradicts data from another study from 
Italy, which did not, however, perform multivariate statistics (Vascellari et al., 2009). There was 
no clear age-related incidence of haemangioma/haemangiosarcoma and mast cell tumour in 
patients >5 years of age. This could indicate the influence of the genetic background or other 
external factors. 
Findings related to the effect of neutering status on tumour development were partly 
dependent on the examination method, specifically on whether the animal was dead or alive at 
the time of diagnosis.  Overall tumour incidence in post-mortem samples was higher in neutered 
than in entire dogs, suggesting bias through investigation of mammary glands and testes in ex-
vivo materials. The difference of the odds ratios for specific tumours in female dogs compared 
with male dogs was small in both sampling groups. Females were at a lower risk for 
haemangioma/haemangiosarcoma and squamous cell carcinoma compared with males, while they 
had a 33.7% higher risk for adenoma/adenocarcinoma overall. In post-mortem samples the risk 
was only 10.6% higher for females than for males. However,  when the neutering status was 
taken into consideration, the difference between the sampling groups was higher, confirming the 
suggested bias mentioned above. 
Neutered dogs were shown to have a higher risk of developing tumours in various 
locations other than the sexual organs, which is consistent with data from other studies (Brønden 
et al., 2010; Torres de la Riva et al., 2013; Zink et al., 2014).  Other authors report that tumour 
risk in the mammary glands in entire dogs is higher than in neutered animals, a finding supported 
by our data (MacVean et al., 1978; Porrello et al., 2006; Brønden et al., 2010; Henry, 2013).  
Neutered male and female dogs showed higher odds ratios for lymphoma and mast cell 
tumour. Neutered female dogs additionally showed higher odds ratios for melanocytic tumours 
and haemangioma/haemangiosarcomas, as did neutered male dogs for adenoma/adenocarcinoma 
and osteoma/osteosarcoma. These correlations need to be validated by future research.  
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In the present study, breed predispositions for neoplasia in general, arranged in 
descending order, were recorded in boxers, cocker spaniels, poodles, Swiss mountain dogs, 
dachshunds, setters, schnauzers and retrievers. In contrast, great Danes, bulldogs, West Highland 
white terriers, Parson Jack Russell terriers, rottweiler, dobermans, collies, shepherds and 
Yorkshire terriers showed a lower risk of developing a tumour compared with crossbreds. 
Other authors report the boxer, the flat coated retriever and the golden retriever (subsets 
of the category of retriever in our study), the Bernese mountain dog and the Saint Bernard 
(subsets of the Swiss mountain dog) and the giant schnauzer (a subset of schnauzer) as being 
more susceptible to tumour development (Brønden et al., 2010; Bell et al., 2012; Dobson, 2013).  
German shepherd dogs were at a lower risk of tumour development in the Danish Veterinary 
Cancer Registry (Brønden et al., 2010). These findings are roughly confirmed by our study, 
taking into account the differences in breed allocation. 
For a better overview and clinical relevance we hereafter only discuss outstanding results 
of the influence of breed on the development of some specific tumours. 
The boxer had an almost five times higher risk (OR 4.926 [CI = 4.343, 5.587]) of developing a 
mast cell tumour and a 1.85 times higher risk of haemangioma/haemangiosarcoma (OR 1.850 [CI 
= 1.506, 2.261]). Similar findings have been described in the literature (Misdorp, 2004; Gough and 
Thomas, 2010). 
The Schnauzer was two times more susceptible for melanocytic tumour and seven times more 
susceptible for squamous cell carcinoma than crossbreds. Melanocytic tumour is known to occur 
more frequently in dogs with darkly pigmented skin or oral mucosa (e.g. schnauzers) (Gough and 
Thomas, 2010; Dobson 2013). The odds ratio for squamous cell carcinoma in the schnauzer was 
higher than expected, which might indicate either a genetic or an environmental factor associated 
with the geographical area from which the samples originate. Gough and Thomas (2010) report a 
predisposition of the schnauzer for squamous cell carcinoma of the digit in a case series. 
The shepherd had higher odds ratios (OR 1.806 [CI = 1.518, 2.150]) of developing a 
haemangioma/haemangiosarcoma, which is consistent with previous reports (Gough and Thomas, 
2010). 
The rottweiler (OR 3.321 [CI = 2.321, 4.752]) and the great Dane (OR 1.936 [CI = 1.248, 
3.003]) had a higher risk of developing an osteoma/osteosarcoma. This tendency has also been 
reported in the literature (Gough and Thomas, 2010).  Reported risk factors for canine 
osteosarcoma are high weight, high height, early neutering and breed predisposition (e.g. Irish 
wolfhound, Saint Bernard, great Dane, rottweiler, Irish setter, doberman pinscher, golden retriever, 
Labrador retriever and Leonberger) (Porrello et al., 2006; Butler et al., 2013).  Genetic factors 
have been observed to differentiate rottweilers and golden retrievers with regard to the incidence 
of spontaneous appendicular osteosarcoma, independent of sex, age and histological classification 
(Thomas et al., 2009). The most significant difference was the deletion of the WT1 gene in 48% of 
the rottweiler tumour cases, while this did not occur in any of the golden retrievers. A recent study 
suggests that ‘weight-bearing stress during the period of high proliferative activity in the long 
bones associated with growth may increase the risk of canine primary bone cancer’ (Anfinsen et 
al., 2015). 
There was, in the present study, no significant difference between mixed breeds and the 
examined breeds/breed categories with regard to general cancer risk, which contrasts with the 
report of Brønden et al. (2007), who showed a twofold increased risk of developing tumours for 
pure breeds compared with mixed breeds. Vascellari et al. (2009), in addition, described the 
estimated crude annual incidence rate for malignant tumours as twofold higher in purebred dogs 
than in crossbreed dogs (Vascellari et al., 2009). Different data collecting or breed definition 
standards might be the reason for these contradictory results. Since the declaration of breed is 
usually provided by the owner of the dog, it is necessary to avoid future uncertainties related to 
breed declaration through genetic testing. Today, the examination of the genome of dogs and the 
identification of single nucleotide polymorphism (SNP) haplotypes allows the classification of 
dog breeds on the basis of genetic relationship (Vonholdt et al., 2010). This will be addressed in a 
follow-up study. Additionally, the breed-related risks found in the present study were confirmed 
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through analysis of the newest data from the Swiss Canine Cancer Registry of 2009 to 2013 (data 
not shown). 
 Small breeds were at a higher risk of developing tumours of the mammary gland and the 
endocrine glands than large breeds. The following tumour locations were less likely in small 
breeds than in large breeds: the respiratory system and intrathoracic organs, the blood and 
hemopoietic system, soft tissues, skin, retroperitoneum and peritoneum, other female sexual 
organs, bones, joints and articular cartilage. Contrasting findings, such as a lower malignant 
mammary tumour incidence in small breed dogs, are suggested by Itoh et al. (2005). Further 
investigations will be necessary to verify those results. The unexpectedly high risk of developing 
tumours of the mammary glands for small breeds in our data could be explained by their 
tendency to have shorter sexual cycles (Arnold-Gloor et al., 2011) and therefore increased 
exposure to sex hormones during oestrus. 
The breeds/breed categories with lower risk of developing osteoma/osteosarcoma were 
breeds of small body size, with the exception of poodles and schnauzers, which show varying body 
sizes. These results suggest that size and castration are predisposing factors for skeletal tumours. 
The large sample size in the present study allowed a detailed insight into the occurrence 
of the most common tumour diagnoses over time and into the influences of age, breed, body size, 
sex and neutering status on canine tumour development. Through the inclusion of influencing 
variables in the statistics, bias factors such as the examination method or the year of diagnosis 
were controlled for. Naturally, not all environmental tumour risk factors were recorded in this 
retrospective cancer registry and therefore could not be included in the statistical evaluation. The 
clinical relevance still has to be elucidated. 
In many cases, the results of the analysis of the Swiss Canine Cancer Registry confirm the 
findings of other authors. In some cases, the results were unique or contradicted other studies, 
implying that further investigations are necessary. 
The reproducibility of cancer epidemiological studies is greatly affected by the absence of 
international standards for veterinary cancer registries (Brønden et al., 2007). In addition, the lack 
of guidelines leads to enormous differences in data collection and consolidation methods among 
existing veterinary cancer registries (Brønden et al., 2007; Vascellari et al., 2009). To achieve a 
more accurate comparison it is crucial to define international de jure standards for veterinary 
cancer registries. It is desirable to collect even more primary information from the canine tumour 
patient for further epidemiological studies of canine cancer, such as type of treatment, diet, age at 
neutering, obesity (body mass index) and body size, the presence of other diseases, vaccination 
status and environmental factors (e.g. exposure to cigarette smoke and other husbandry conditions, 
daily exercise). 
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6. Supplemental material 
Table 1 Distribution of tumour diagnoses. The tumour diagnoses analyzed in the present 
study are printed in bold. 
Tumour Frequency 
Adenoma, adenocarcinoma (ICD-O 8140) 12,293 (18.09%) 
Complex mixed tumor, neoplasia of stroma (ICD-O 8940) 6,465 (9.52%) 
Mast cell tumour (ICD-O 9740) 4,415 (6.50%) 
Lipoma (ICD-O 8850) 3,522 (5.18%) 
Unclassified neoplasm (ICD-O 8000) 2,775 (4.08%) 
Lymphoma (ICD-O 9590, 9591, 9700) 2,955 (4.35%) 
Melanocytic tumour (ICD-O 8720, 8730) 2,466 (3.63%) 
Adenocarcinoma of anal glands (ICD-O 8215) 2,420 (3.56%) 
Soft tissue tumour (ICD-O 8800) 2,315 (3.41%) 
Fibroma, fibrosarcoma (ICD-O 8810, 8812)  2,309 (3.40%) 
Hemangioma/hemangiosarcoma (ICD-O 9120) 1,904 (2.80%) 
Histiocytoma (ICD-O 8831) 1,686 (2.48%) 
Epithelial tumor (ICD-O 8010) 1,677 (2.47%) 
Dermatofibroma, dermatofibrosarcoma (ICD-O 8832) 1,585 (2.33%) 
Sebaceous adenoma, sebaceous adenocarcinoma (ICD-O 8410) 1,456 (2.14%) 
Hemangiopericytoma (ICD-O 9150) 1,256 (1.85%) 
Squamous cell carcinoma (ICD-O 8070, 8071, 8078) 1,324 (1.95%) 
Trichoepithelioma (ICD-O 8100) 1,116 (1.64%) 
Epithelioma (ICD-O 8011) 958 (1.41%) 
Papillary carcinoma (ICD-O 8050) 871 (1.28%) 
Osteoma/osteosarcoma (ICD-O 9180) 842 (1.24%) 
Hemangioendothelioma, hemangioendotheliosarcoma (ICD-O 
9130) 622 (0.92%) 
Seminoma (ICD-O 9061) 618 (0.91%) 
Spindle cell sarcoma (ICD-O 8801) 547 (0.81%) 
Leiomyoma (ICD-O 8890) 538 (0.79%) 
Plasmacytoma (ICD-O 9731) 520 (0.77%) 
Pilomatrixoma (ICD-O 8110) 503 (0.74%) 
Leydig cell tumor (ICD-O 8650) 450 (0.66%) 
Sweat gland adenoma, sweat gland adenocarcinoma (ICD-O 
8400) 427 (0.63%) 
Sertoli cell adenoma, sertoli cell carcinoma (ICD-O 8640) 423 (0.62%) 
Basal cell tumour 413 (0.61%) 
Langerhans cell histiocytosis (ICD-O 9751) 356 (0.52%) 
Secretory carcinoma of breast (ICD-O 8502) 329 (0.48%) 
Adenomatous polyp, adenocarcinoma in adenomatous polyp 
(ICD-O 8210) 321 (0.47%) 
Carcinoma, anaplastic type (ICD-O 8021) 296 (0.44%) 
Malignant histiocytosis (ICD-O 9750) 287 (0.42%) 
Multifocal superficial basal cell carcinoma (ICD-O 8091) 231 (0.34%) 
Myxoma, myxosarcoma (ICD-O 8840) 209 (0.31%) 
Ameloblastic fibroma, ameloblastic fibrosarcoma (ICD-O 9330) 197 (0.29%) 
Adenocarcinoma with squamous metaplasia (ICD-O 8570) 190 (0.28%) 
Magnocellular nevus (ICD-O 8726) 185 (0.27%) 
Leukemia (ICD-O 9800) 178 (0.26%) 
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Chondroma, chondrosarcoma (ICD-O 9220) 168 (0.25%) 
Adrenal cortical adenoma, adrenal cortical adenocarcinoma 
(ICD-O 8370) 168 (0.25%) 
Transitional cell papilloma, transitional cell carcinoma (ICD-O 
8120) 168 (0.25%) 
Hepatoma, hepatocarcinoma (ICD-O 8170) 155 (0.23%) 
Papillary adenoma, adenocarcinoma (ICD-O 8260) 112 (0.16%) 
Meningioma (ICD-O 9530) 111 (0.16%) 
Adamantinoma of the jaw (ICD-O 9261) 103 (0.15%) 
Fibrolipoma, liposarcoma (ICD-O 8851) 103 (0.15%) 
Chemodectoma (ICD-O 8693) 101 (0.15%) 
Fibrous histiocytoma (ICD-O 8830) 98 (0.14%) 
Thymoma (ICD-O 8580) 96 (0.14%) 
Round cell sarcoma (ICD-O 8803) 95 (0.14%) 
Fibromyxoma, fibromyxosarcoma (ICD-O 8811) 93 (0.14%) 
Sertoli-Leydig cell tumor (ICD-O 8631) 92 (0.14%) 
Histiocytic sarcoma (ICD-O 9755) 88 (0.13%) 
Fibroepithelial basal cell carcinoma (ICD-O 8093) 86 (0.13%) 
Glioma (ICD-O 9380) 83 (0.12%) 
Intracystic papillary adenoma, intracystic papillary 
adenocarcinoma (ICD-O 8504) 79 (0.12%) 
Granulosa cell tumour, granulosa cell carcinoma (ICD-O 8620) 75 (0.11%) 
Spindle cell carcinoma (ICD-O 8032) 72 (0.11%) 
Neurilemmoma (ICD-O 9560) 69 (0.10%) 
Other tumours (frequency < 64, percentage < 0.1%) 1,278 (1.86%) 
All tumour diagnoses (ICD-O 8000 – 9930) 67,943 (100%) 
  
 37 
Table 2 The distribution of tumour locations in male dogs (all examination methods). 
 
Number and relative percentage of occurrences in 
Tumour location intact males castrated males all males 
Skin ICD-O C 44 5,181 (34.81%) 1,578 (35.64%) 6,759 (35.00%) 
Unspecified location ICD-O C 80 2,486 (16.70%) 849 (19.18%) 3,335 (17.27%) 
Soft tissues ICD-O C 49 2,378 (15.98%) 954 (21.55%) 3,332 (17.25%) 
Gastrointestinal tract ICD-O C 16-26.8 1,361 (9.14%) 386 (8.72%) 1,747 (9.05%) 
Testes ICD-O C 62 1,360 (9.14%) 0 (0.00%) 1,360 (7.04%) 
Other male sexual organs (penis, prostate 
gland, scrotum) ICD-O C 60, 61, 63.2 127 (0.85%) 37 (0.84%) 164 (0.85%) 
Neoplasia of bones, joints, cartilage ICD-
O C40-41 332 (2.23%) 122 (2.76%) 454 (2.35%) 
Oral cavitiy, pharynx ICD-O 2.9-11 306 (2.06%) 94 (2.12%) 400 (2.07%) 
Mammary gland ICD-O C 50 323 (2.17%) 71 (1.60%) 394 (2.04%) 
Respiratory system, intrathoracic organs 
ICD-O C 30-39 292 (1.96%) 97 (2.19%) 389 (2.01%) 
Blood, hematopoietic system ICD-O C42 213 (1.43%) 85 (1.92%) 298 (1.54%) 
Endocrine gland ICD-O C 73-75 203 (1.36%) 64 (1.45%) 267 (1.38%) 
Lymph nodes ICD-O C 77 95 (0.64%) 29 (0.66%) 124 (0.64%) 
Urinary organs ICD-O C 67-68 81 (0.54%) 26 (0.59%) 107 (0.55%) 
Other tumour locations 146 (0.98%) 35 (0.79%) 65 (0.34%) 
All tumour locations ICD-O C 2.9-80 14,884 (100%) 4,427 (100%) 19,311 (100%) 
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Table 3 The distribution of tumour locations in male dogs (post mortem samples). 
 
Number and relative percentage of 
occurrences in 
Tumour location 
intact males castrated 
males 
all males 
Unspecified location ICD-O C 80 316 (16.34%) 90 (19.69%) 406 (16.98%) 
Gastrointestinal tract ICD-O C 16-26.8 266 (13.75%) 66 (14.44%) 332 (13.89%) 
Respiratory system, intrathoracic organs 
ICD-O C 30-39 231 (11.94%) 73 (15.97%) 304 (12.71%) 
Soft tissues ICD-O C 49 229 (11.84%) 50 (10.94%) 279 (11.67%) 
Testes ICD-O C 62 187 (9.67%) 0 (0.00%) 187 (7.82%) 
Other male sexual organs (penis, prostate 
gland, scrotum) ICD-O C 60, 61, 63.2 65 (3.36%) 18 (3.94%) 83 (3.47%) 
Endocrine gland ICD-O C 73-75 146 (7.55%) 37 (8.10%) 183 (7.65%) 
Skin ICD-O C 44 108 (5.58%) 30 (6.56%) 138 (5.77%) 
Neoplasia of bones, joints, cartilage ICD-
O C40-41 93 (4.81%) 20 (4.38%) 113 (4.73%) 
Blood, hematopoietic system ICD-O C42 69 (3.57%) 29 (6.35%) 98 (4.10%) 
Urinary organs ICD-O C 67-68 44 (2.28%) 13 (2.84%) 57 (2.38%) 
Oral cavitiy, pharynx ICD-O 2.9-11 53 (2.74%) 2 (0.44%) 55 (2.30%) 
Lymph nodes ICD-O C 77 42 (2.17%) 9 (1.97%) 51 (2.13%) 
Mammary gland ICD-O C 50 12 (0.62%) 1 (0.22%) 13 (0.54%) 
Other tumour locations 73 (3.77%) 19 (4.16%) 92 (3.85%) 
All tumour locations ICD-O C 2.9-80 1,934 (100%) 457 (100%) 2,391 (100%) 
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Table 4 The distribution of tumour locations in female dogs in ex vivo and post mortem 
samples. 
 
Number and relative percentage of occurrences in 
Tumour location 
intact females castrated 
females 
all females 
Skin ICD-O C 44 4,062 (26.89%) 3,152 (33.06%) 7,214 (29.28%) 
Mammary gland ICD-O C 50 4,544 (30.08%) 1,191 (12.49%) 5,735 (23.28%) 
Unspecified location ICD-O C 80 2,355 (15.59%) 1,702 (17.85%) 4,057 (16.47%) 
Soft tissues ICD-O C 49 2,108 (13.96%) 1,908 (20.01%) 4,016 (16.3%) 
Gastrointestinal tract ICD-O C 16-
26.8 594 (3.93%) 482 (5.06%) 1,076 (4.37%) 
Neoplasia of bones, joints, cartilage 
ICD-O C40-41 270 (1.79%) 208 (2.18%) 478 (1.94%) 
Respiratory system, intrathoracic 
organs ICD-O C 30-39 239 (1.58%) 204 (2.14%) 443 (1.80%) 
Oral cavitiy, pharynx ICD-O 2.9-11 211 (1.40%) 170 (1.78%) 381 (1.55%) 
Blood, hematopoietic system ICD-O 
C42 138 (0.91%) 136 (1.43%) 274 (1.11%) 
Endocrine gland ICD-O C 73-75 173 (1.15%) 100 (1.05%) 273 (1.11%) 
Other female sexual organs (vagina, 
uterus, ovary) ICD-O C 52-57 133 (0.88%) 69 (0.72%) 202 (0.82%) 
Urinary organs ICD-O C 67-68 76 (0.50%) 71 (0.74%) 147 (0.60%) 
Lymph nodes ICD-O C 77 62 (0.41%) 37 (0.39%) 99 (0.40%) 
Other tumour locations 140 (0.93%) 104 (1.09%) 244 (0.99%) 
All tumour locations ICD-O C 2.9-80 15,105 (100%) 9,534 (100%) 2,4639 (100%) 
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Table 5 The distribution of tumour locations in female dogs in post mortem samples. 
 
Number and relative percentage of occurrences 
in 
Tumour location 
intact females castrated 
females 
all females 
Unspecified location ICD-O C 80 209 (15.13%) 171 (19.81%) 380 (16.93%) 
Respiratory system, intrathoracic 
organs ICD-O C 30-39 175 (12.67%) 146 (16.92%) 321 (14.30%) 
Mammary gland ICD-O C 50 267 (19.33%) 45 (5.21%) 312 (13.90%) 
Gastrointestinal tract ICD-O C 16-26.8 168 (12.17%) 126 (14.6%) 294 (13.10%) 
Endocrine gland ICD-O C 73-75 140 (10.14%) 59 (6.84%) 199 (8.87%) 
Soft tissues ICD-O C 49 101 (7.31%) 96 (11.12%) 197 (8.78%) 
Skin ICD-O C 44 63 (4.56%) 44 (5.10%) 107 (4.77%) 
Neoplasia of bones, joints, cartilage 
ICD-O C40-41 62 (4.49%) 30 (3.48%) 92 (4.10%) 
Blood, hematopoietic system ICD-O 
C42 46 (3.33%) 42 (4.87%) 88 (3.92%) 
Urinary organs ICD-O C 67-68 31 (2.24%) 35 (4.06%) 66 (2.94%) 
Brain, meninges, other parts of CNS 
ICD-O C 70-72 26 (1.88%) 27 (3.13%) 53 (2.36%) 
Other female sexual organs (vagina, 
uterus, ovary) ICD-O C 52-57 39 (2.82%) 5 (0.58%) 44 (1.96%) 
Lymph nodes ICD-O C 77 22 (1.59%) 8 (0.93%) 30 (1.34%) 
Oral cavitiy, pharynx ICD-O 2.9-11 13 (0.94%) 17 (1.97%) 30 (1.34%) 
Other tumour locations 19 (1.36%) 12 (1.39%) 31 (1.38%) 
All tumour locations ICD-O C 2.9-80 1,381 (100%) 863 (100%) 2,244 (100%) 
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Table 6 Risk of developing the most common tumour types, comparing castrated females and 
intact females and sampling methods. Tumours of the mammary gland were excluded. 
Statistically significant results are in bold. The number of observations was: 140,652; 2 5,832. 
  Neutered females compared to intact females (OR=1) 
   in ex vivo and post mortem samples1 
 in post mortem 
samples2 
Tumour type OR & [95%CI] OR & [95%CI] 
Adenoma, adenocarcinoma 0.889 [0.795, 0.994] 1.522 [1.218, 1.903] 
Fibroma, fibrosarcoma 1.046 [0.893, 1.226] 1.155 [0.568, 2.351] 
Hemangioma, hemangiosarcoma 1.425 [1.217, 1.670] 2.379 [1.565, 3.618] 
Lymphoma 1.277 [1.30, 1.443] 2.293 [1.688, 3.115] 
Mast cell tumour 1.066 [0.967, 1.175] 2.926 [1.324, 6.465] 
Melanocytic tumour 1.243 [1.075, 1.439] 4.398 [1.597, 12.112] 
Osteoma, osteosarcoma 1.121 [0.907, 1.386] 1.315 [0.818, 2.114] 
Squamous cell carcinoma  1.125 [0.917, 1.379] 1.953 [0.495, 7.696] 
 
Table 7 Risk of developing a tumour in the most common locations, comparing castrated 
females and intact females and sampling methods. Tumours of the  mammary gland were 
excluded. Significant results are in bold. The number of observations was: 1 40,652; 2 5,832. 
    Neutered females vs. intact females (OR=1) 
    
in ex vivo and post 
mortem samples1 
in post mortem 
samples2 
Tumour location OR & [95%CI] OR & [95%CI] 
Skin 0.997 [0.946, 1.051] 1.823 [1.188, 2.796] 
Soft tissues  1.189 [1.119, 1.271] 2.182 [1.603, 2.972] 
Blood, hematopoietic system  1.497 [1.168, 1.918] 1.924 [1.219, 3.035] 
Bones, joints, cartilage  1.120 [0.929, 1.351] 1.113 [0.699, 1.772] 
Endocrine gland  1.235 [0.945, 1.613] 1.078 [0.772, 1.504] 
Gastrointestinal tract  1.298 [1.143, 1.475] 1.939 [1.495, 2.515] 
Lymph nodes  1.000 [0.650, 1.536] 1.117 [0.456, 2.739] 
Other female sexual organs (vagina, uterus, ovary) 0.835 [0.617, 1.130] 0.324 [0.124, 0.850] 
Oral cavity, pharynx  1.105 [0.897, 1.361] 4.720 [1.983, 11.232] 
Respiratory system, intrathoracic organs  1.520 [1.245, 1.857] 1.742 [1.367, 2.219] 
Urinary organs  1.577 [1.120, 2.220] 2.606 [1.532, 4.434] 
Unspecified location 0.952 [0.890, 1.018] 1.763 [1.408, 2.207] 
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